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Scientific environment  
This project started out as a co-operation between clinicians and geneticists at the 
University of Bergen, and during its course it has involved other national and 
international research groups, above all the Norwegian Centre for Primary Sclerosing 
Cholangitis (NoPSC), Oslo University Hospital, Rikshospitalet lead by professor 
Tom Hemming Karlsen.  
Patients with Familial GUCY2C diarrhoea syndrome were followed up at the 
Department of Paediatrics, the Department of Gastroenterology and at the 
Department of Medical Genetics, Haukeland University Hospital. Much of the 
genomic investigations depended on the research infrastructure provided by the 
Genomics Core Facility at the University of Bergen.   
During the project I twice a year attended the NoPSC guest professor meetings, 
where I presented, discussed and got advice on my research with world leading 
experts on microbiota and genetics in inflammatory bowel disease (IBD). These 
meetings provided the basis for our co-operation with the Institute of Clinical 
Molecular Biology, University of Kiel, Germany, where genotyping of IBD genetic 
risk variants was performed.   
The project also depended on co-operation with the Indian Institute of Science, under 
prof. S. Visweswariah, Bangalore, India, which contributed with functional studies of 
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We studied a large Norwegian family who had been affected by chronic diarrhoea 
and other symptoms from the digestive tract throughout several generations. Our 
genetic studies showed that family members with diarrhoea shared markers on the 
short arm of chromosome 12. In this part of the genome we discovered a new genetic 
variant in GUCY2C. This variant was present in 32 family members with diarrhoea, 
but not in the healthy family members. We performed functional assays of the 
GUCY2C variant in a cell-model. These studies showed that the genetic variant 
encodes an increased activity of guanylate cyclase C (GC-C), a protein known to be 
involved in infectious diarrhoea.  
Apart from diarrhoea many family members had also experienced acute intestinal 
obstructions and/or inflammatory bowel disease (IBD) categorized as Crohn’s disease 
(CD). To our knowledge the constellation of symptoms experienced by our patients 
had not been reported previously and we assumed that we were dealing with a new 
disorder. We called this disorder Familial GUCY2C diarrhoea syndrome (FGDS). The 
publication in 2012 of our research constituted the first report of a human disorder 
caused by a change in the GUCY2C gene.  
The further work on this thesis aimed at discovering factors involved in the 
pathogenesis of FGDS with a main focus on its link to IBD.  
In parallel with our project multinational case-control studies were charting the 
genetic basis for IBD, and by 2015 more than 200 genetic associations had been 
identified. While GUCY2C has not been flagged by these population-based studies 
we hypothesised that common genetic variants within the GC-C pathway may still 
contribute to the risk of developing IBD. Rather than assessing single genes, we 
tested whether an aggregation of genes within the GC-C pathway was associated with 
IBD. For this analysis we used genetic association statistics made publicly available 
from the largest IBD case-control studies. The GC-C gene list did indeed show 





We then looked at common IBD genetic risk variants in FGDS patients and found 
that genetic variants in the NOD2 gene distinguished FGDS patients affected by IBD 
from those not developing IBD. NOD2 encodes a protein involved in sensing and 
removal of bacteria in the intestinal wall.   
We studied which genes were differentially expressed in the distal small bowel of 
FGDS compared to healthy controls as well as patients with CD. Down regulation of 
metallothionein genes was found in FGDS patients regardless of concomitant IBD 
when compared to healthy but not when compared to CD. Metallothioneins may 
serve as signal transducers in the interplay between the human host and its resident 
bacteria (microbiota). Paucity of these antioxidant proteins may perturb epithelial 
sensing and clearance of microbes and has been reported in IBD.  
We hypothesised that GUCY2C related changes of the gut hydration could also 
impact on its bacterial composition. Using sequencing of the 16S ribosomal RNA 
gene we analysed the microbial composition in stool from adult FGDS patients, 
related and unrelated healthy controls as well as patients with IBD. Overall 
microbiota composition of FGDS patients was different from the other groups, but 
similar between healthy relatives and unrelated healthy controls. The microbiota of 
the FGDS patients displayed increased abundance of Enterobacteriaceae and loss of 
Faecalibacterium, findings that may have a pro-inflammatory potential and are found 
in IBD.  
In conclusion we here identified activating mutations of the GUCY2C gene as the 
cause of familial diarrhoea and defined a new disorder, Familial GUCY2C diarrhoea 
syndrome. Our work indicates that genetic testing for mutations in GUCY2C should 
be considered in patients presenting with early onset secretory diarrhoea. Apart from 
diarrhoea we also highlighted clinical complications potentially linked to 
hyperactivation of GUCY2C, such as IBD, intestinal obstruction and dysfunctional 
gut peristalsis. Our subsequent studies suggested that GUCY2C is involved in the 
crosstalk between the gut mucosa and the adjacent microbiota, providing a potential 
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Diarrhoea takes a high toll on health worldwide and is a major cause of childhood 
death in low-and middle-income societies.1 Most episodes of diarrhoea are self-
limited and are commonly elicited by heat stable bacterial toxins binding to the 
epithelial enzyme linked receptor guanylate cyclase C (GC-C).2 This thesis deals with 
our discovery and characterization of a novel human diarrheal disorder and its cause, 
an inheritable change in GC-C function.  
Genetic linkage analysis and sequencing helped to identify a previously unknown 
mutation in the gene GUCY2C (which encodes GC-C) as the cause of childhood 
onset chronic diarrhoea in 32 members of a large Norwegian family. The mutation is 
a so-called “gain of function” that increases GC-C activity. We named the disorder 
Familial GUCY2C diarrhoea syndrome (FGDS) referring to the mutated gene and the 
concurrence of diarrhoea with other intestinal symptoms experienced by these 
patients.  
Finding the causative mutation of this rare monogenic disorder constituted the initial 
element of this thesis, offering the prospect of new insights along two main avenues.  
Firstly existing and future knowledge about GC-C could be exploited to better 
understand the disorder, and secondly our studies of FGDS may reveal new 
knowledge on GUCY2C, the function of GC-C and more broadly about the pathways 
related to GC-C signalling.3 More than 20% of the FGDS patients had been 
diagnosed with Crohn’s disease (CD), one of the two main types of the inflammatory 
bowel diseases (IBD).  This observation strongly suggested that GC-C deregulation 
influences the risk for development of IBD. After our initial discovery and 
characterization of FGDS we aimed at identifying factors that could help to 
understand the clinical presentation and variable complications of this disorder, 
focussing on the link between GC-C deregulation and IBD. This had previously only 





Our project coincided in time with large international case-control studies (genome-
wide association studies, GWAS) that were fruitful in mapping the genetic basis of 
IBD, opening similar opportunities for disclosing functional implications of the 
genetic associations. In IBD as a complex genetic trait, most of the individual genetic 
risk factors are common in the population and the impact on disease development of 
each variant may be modest and operate only when interacting in complex manners 
with other genetic and non–genetic factors. Our study aimed at helping to bridge this 
gap by further characterizing the effects of a GUCY2C mutation, which high 
functional impact was evident clinically as well as in the laboratory. We also 
evaluated whether these effects could be relevant for development of IBD in nearly 
one in four adult FGDS patients. Finally, the study of patients with this GC-C 
activating disorder might clarify unknown biological effects of the recently approved 
GC-C activating drugs.4, 6, 7, 8  
This thesis gives first an introduction that presents an overview of diarrheal disorders, 
emphasising on IBD, the role of genetics and the intestinal microbiota. A vocabulary 
is provided. Aims for the different subprojects are presented followed by a section 
covering methodological considerations. Next a summary of findings is presented. 
Lastly the discussion examines the conclusions drawn in the subprojects. A section is 
dedicated to how the study might help to guide management of FGDS and ultimately 
suggestions for topics of further studies are given. 
1.1 Diarrhoea	  
Diarrhoea, defined as the passage of 3 or more liquid stools per day, results from an 
imbalance of secretion and absorption of fluids in the gastrointestinal tract. Although 
most episodes of diarrhoea are self-limiting, electrolyte and fluid losses can be large 
enough to result in cardiovascular collapse and death. Diarrhoea may also impair 
uptake of micro- and macronutrients, leading to malnutrition, impaired immune 
defences and a vicious circle of recurrent or persistent diarrhoea.1 Worldwide an 
estimated 800.000 pre-school children die each year as a consequence of diarrhoea, 





diarrhoea are thus highly prioritized measures to improve global public health. The 
most frequent infectious agents underlying moderate to severe diarrhoea and hence 
important targets of interventions are rotavirus, enterotoxigenic Escherichia coli 
(ETEC), cryptosporidium and Shigella.1 By mimicking intestinal peptides, heat stable 
toxins produced by ETEC activate GC-C and thus increase formation of the second 
messenger cyclic guanosine monophosphate (cGMP), eliciting a chain of reactions 
resulting in net secretion of ions and fluids across the intestinal epithelium.10 Two 
crucial steps in this cascade, the inhibition of sodium/ hydrogen exchange (NHE) 
channels and the opening of the cystic fibrosis conductance regulator (CFTR) are 
shared by other diarrhoea inducing agents (e.g. Vibrio Cholera) employing the 
second messenger cyclic adenosine monophosphate (cAMP).11  
The current study was performed in an affluent society in which improvements in 
nutrition, hygiene and health care during the last century have reduced the incidence 
and severity of infectious diarrhoea.12 (https://ourworldindata.org/health-meta) 
Life style changes in the same period have been associated with an increased 
prevalence of other diarrheal disorders such as coeliac disease and IBD.13, 14 Patients 
with coeliac disease are to a large extent helped by the fact that the key 
environmental trigger, gluten, is known and can be avoided in the diet. What triggers 
and sustains IBD remains to be defined, but in both these common disorders, 
inheritable factors interacting with intestinal bacteria may play a crucial role.15, 16  
Technological advances in the field of genetics have paved the way not only for 
detection of the inheritable basis of diarrheal disorders, but also allowed snapshots of 
intestinal biological processes, such as tissue gene expression, and the composition of 
the gut microbiota.17, 18, 19, 20 To what extent these insights may help to delineate 
pathogenic mechanisms, may however rely on how well knowledge about genetic 
factors associated with disease can be combined with knowledge about the relevant 
biological processes which they involve.21  
One important challenge herein relate to the fact that the outcome in common 





non-genetic factors, where the individual effects may be hard to discern. Rare familial 
diarrheal disorders may make an exception since they are usually governed by high 
impact changes in a single gene.  
1.1.1 Monogenic	  diarrheal	  disorders	  
Cystic fibrosis (CF) is the most common monogenic disorder causing diarrhoea in the 
Caucasian population, with a birth incidence in the range of 1/1,600- 1/5,000. That 
maldigestive diarrhoea in this disorder results from pancreatic enzyme deficiency has 
since long been appreciated and can be remedied by enzyme replacement, but CF still 
remains a serious disorder leading to lung destruction and a median survival ~ 40 
years.22 The discovery and mapping of the genetic changes underlying CF have been 
crucial to understand disease mechanisms including perturbed chloride transport 
across epithelia, mucus changes, obstruction of pancreatic ducts and chronic airways 
disease due to functional changes in the ion channel CFTR.23 The importance of 
genetics can hardly be overemphasised in CF and is now expanding from basic 
science and diagnostics, to tailoring treatment with drugs that specifically target 
different CFTR defects, providing a realistic hope of substantially improving the 
outcome in this disorder.24, 25, 26, 27  
Three brothers in the family described in this thesis were referred to genetic 
evaluation almost 20 years ago. The geneticist noted that their early onset diarrhoea 
with dehydration and increased sodium in the stools resembled congenital sodium 
diarrhoea (CSD), although showing a milder presentation and a different pattern of 
inheritance than CSD. At that time the tools for studying genetics were fewer, and the 
molecular basis for CSD as well as many other inheritable diarrheal disorders was 
still not known.28 In the following years genetics have helped to reveal the molecular 
basis for many diarrheal disorders, to diagnose and to inform about prognosis and 
therapeutic opportunities.29, 30, 31, 32, 33 The evolving spectrum of monogenic diarrheal 
disorders show that the aetiology of diarrhoea is variable, usually belonging to at least 
one of 5 categories: 





2) Disorders of epithelial digestive enzymes (e.g. sucrose-isomaltase deficiency) 
3) Disorders of lipid transport (e.g. chylomicron retention disease) 
4) Disorders of epithelial architecture (e.g. tufting enteropathy) 
5) Disorders of immune function (e.g. very early onset IBD) 
About half of the roughly 7000 monogenic disorders listed in the OMIM database 
had the genetic cause resolved by 2013, partially owing to the decreasing cost and 
increasing availability of high-throughput genetic sequencing.34 Predictions that the 
genetic cause of all these disorders will be resolved by 2020 may overly optimistic, 
e.g. given the challenges relating to discovery and verification of variants that reside 
outside the coding parts of the genome.34  
1.2 The	  human	  genome	  and	  genetic	  variation	  
Every human somatic cell contains a full genome, which consists of 3 billion pairs of 
nucleotide bases arranged in 23 pairs of chromosomes. The information held by the 
genome, depends on the order of 4 different bases, adenine (A), cytosine (C), guanine 
(G), and thymine (T).  The chain of bases is covalently linked to a complimentary 
strand where A combines with T and G with C (Figure 1). The dynamic properties of 
this double-strand structure, the deoxyribonucleotide acid (DNA) double helix allows 
the genome to be copied, translated into proteins and to be repaired.  
Only 1.5 percent of the genome encodes proteins. This fraction, called the exome, is 
divided in 180,000 coding sequences (exons) and roughly 25,000 genes.35 The 
remaining part of the genome consists of intergenic regions and intragenic non-
coding regions (introns). Except for the male Y and X chromosomes there are 2 
copies of each gene and chromosome. Each nucleotide has thus a corresponding 
partner on another chromosome. Human genetic diversity is due to variations in 
single nucleotides (SNPs, Figure 1), such as substitution of one nucleotide with 
another, deletions or insertions or due to variations in larger segments of the genome 





position is called the allele of a gene. The combination of two alleles on a 
chromosome pair then defines the genotype at that position.  
When the alleles at a certain position on the chromosome pairs share the same 
nucleotide, they are defined as homozygous. In the case of nucleotide discrepancy 
they are referred to as heterozygous. Allelic variation may or may not affect gene 
function. Genetic variants resulting in reduced functions of the protein (loss-of-
function) may have no or minimal impact on the organism if affecting only one allele, 
but tend to be more harmful if homozygous. On the other hand heterozygous allelic 
variants are more likely to cause observable traits or disease when conferring a gain-
of-gene-function. Across generations, the frequency of these alterations may be 
subject to selective pressure leading to evolution of the trait. 
 One frequent aim of genetic studies is to resolve whether allelic variants impact on 
susceptibility for disease. In genetic terminology, “phenotype” is the term used for 
the disease or clinical features of the disease / trait that is under study. Single gene 
disorders display a strong genotype-phenotype correlation, and may be inherited in an 
autosomal dominant (requiring only heterozygosity for the less common allele) or 
recessive (requiring homozygosity for the minor allele) inheritance pattern.  
The genetic constitution of an individual is inherited from the parents, who both 
contribute with a single version of each chromosome carried by the reproductive cell 
(in contrast to the somatic cell that carries a pair of each chromosome).  The genetic 
code stored in the reproductive cell is again the result of an exchange (recombination) 
of material that took place before conception between the parent chromosome pairs. 
Despite this recombination, sequences that are spatially close tend to be inherited 
together, i.e. display linkage. Within families linkage between neighbouring genetic 
variants helps to track the segregation of disease-causing genetic variants using 
linkage analysis.  
At the population level, the degree to which genetic variants display linkage is 





and of the normal genetic variation is vital in case control-studies studies aiming at 
identifying disease associated genes.36 
 
Figure	  1.	  The	  human	  genome	  is	  organised	  in	  double	  strand	  (DNA)	  helices	  
containing	  a	  sequence	  of	  4	  types	  of	  bases	  (A,	  T,	  C,	  G)	  that	  make	  up	  the	  
genetic	  code.	  Each	  strand	  is	  covalently	  linked	  to	  the	  complimentary	  
opposite	  strand	  where	  A	  links	  with	  T	  and	  G	  links	  with	  C.	  Variation	  of	  base	  






















Table 1. Vocabulary 
Allele Each of two or more alternative variants (of 
a gene) at a given chromosomal position. 
Alpha diversity Ecological diversity (e.g. richness of 
species) within a sample. 
Amplification 
 
Increasing the amount of a specified DNA 
sequence e.g. by PCR. 
Amplicon The product of amplification / replication. 
Beta diversity Ecological diversity between samples. 
Endogenous Originating within the organism. 
Genotype The particular combination of alleles at a 
specific genetic locus. 
Genus (pl. genera) The taxonomic level below family and 
above species. 
Genome The totality of genetic information of a cell 
or an organism. 
Genomics Study of DNA sequences and properties of 
entire genomes. 
Haplotype A specific combination of 2 or more alleles 
on a single chromosome.  
HEK293 Human Embryonic Kidney 293 cells, an 
epithelial cell line used as a cell-model.  
Heterozygous Having different alleles on the two 
chromosomes at a particular locus. 
Homozygous Having identical alleles on the two 
chromosomes at a particular locus. 
Horizontal gene transfer Passage of genes from one organism to 
another independent of cell division. E.g. 
virulence factors or antibiotic resistance.  
Hybridization Joining together two complementary strands 
of DNA from different sources. 
Ileocolonoscopy Inspection of the large bowel and distal 
small bowel with a flexible endoscope. 
Ileum The distal part of the small bowel.  
Library Collection of DNA fragments originating 
from an organism or a sample (e.g. stools). 
Linkage disequilibrium (LD) Non-random concurrence in the population 
of specific genetic variants at different 
positions mainly accounted for by their 
physical proximity on the chromosome. 





Nominal significance A significance level / p-value not adjusted 
for multiple testing. 
Penetrance The degree to which a genetic change leads 
to a specific trait. 
Permutation analysis Statistical analysis using a 0-distribution 
created by repetitive shuffling of labels. 
(class / phenotype / gene)  Phenotype The observable ( .g. physical, biochemical) 
characteristics of an individual. Genotype is 
the genetic contribution to phenotype. 
Phylum (pl. phyla) The taxonomic level below kingdom and 
above class. 
Plasmid Small circular DNA molecule that replicates 
independently of the genome. 
Recombination Process in which DNA molecules are 
broken and re-joined in new combinations. 
E.g. cross over during meiosis. 
Single nucleotide polymorphism (SNP) Variation in a single nucleotide at a specific 
position that occurs to an appreciable 
degree (>1%) in the population. 
Taxon (pl. taxa) A group of organisms that are evolutionary 
related. In taxonomy low rank taxa are 
aggregated to form higher rank (more 
generic) taxa.  
Taxonomy Defining and naming groups of organisms 
according to evolutionary relationships. 
Organisms are grouped according to a 
hierarchy of taxonomic levels with the 
highest level being the most generic 
(kingdom) and the lowest level the most 
specific (species).  
Transcription Copying of one strand of DNA into a 
complementary RNA sequence. 
Type I error False positive test result. 
Type II error False negative test result. 
UniFrac A distance metric that incorporates 
information about relative phylogenetic 
relatedness, used to compare biological 
communities. 
Volvulus Rotation of mesenterium and intestine 
leading to obstruction. 






1.2.1 Monogenic	  versus	  complex	  diseases	  
In medical genetics we are concerned with how human diseases and related traits 
(phenotypes) are influenced by genetic variation. High blood pressure and tall stature 
are examples of phenotypes that are partially inheritable. Blood pressure may be 
determined by a combination of several genes, environmental exposures and life style 
such as smoking, diet and exercise, and is thus regarded as a complex or polygenic 
trait. In contrast, two copies of the F508del variant in the CFTR gene inherited from 
healthy, heterozygous carriers inevitably leads to the serious disorder CF. Since CF is 
caused by variants in only one gene (CFTR), it is called a monogenic disorder. 
However other genes and environmental exposures do affect the phenotype in 
monogenic disorders. For instance, approximately 15 % of CF neonates presents with 
severe intestinal obstruction due to impaction of sticky meconium. A comparison of 
CF patients with and without this complication (called meconium ileus) has revealed 
that the added burden of common genetic variation (SNPs) in ion channels other than 
CFTR may determine this severe phenotype.37 Similarly other genetic variants (in 
different pathways) may aggravate liver injury in CF.38 
Finding genetic variants (modifier genes) that impact on the phenotype may help to 
further understand disease mechanisms in monogenic diseases.39  
The distinction between monogenic and complex disorders is conceptually useful, but 
in reality genetic disorders exist along a spectrum, where alterations in one or a few 
genes can have high or low impact on development of a phenotype, with the number 
of genetic and non-genetic factors interacting in causing disease being higher in 
complex disorders (Figure 2).  Monogenic and complex disorders that are 
phenotypically similar may display genetic overlap, suggesting that shared 
mechanisms are involved. Studies of IBD provide a relevant example, where rare 
variants in IL10RA encoding the interleukin 10 receptor, impair development of 
tolerance to gut bacteria and give rise to severe “Very early onset IBD”, while 
common variants in the IL10 gene contribute to the polygenic risk for conventional 






Figure	  2.	  The	  rectangle	  schematically	  illustrates	  the	  relationship	  between	  
genetic	  (orange)	  and	  environmental	  (blue)	  contribution	  to	  selected	  
diarrheal	  disorders,	  and	  suggests	  a	  concept	  where	  there	  is	  a	  continuum	  
between	  monogenic	  and	  complex	  (polygenic)	  disorders.	  Single	  genes	  play	  a	  
dominant	  role	  in	  monogenic	  disorders	  (e.g.	  CFTR	  in	  cystic	  fibrosis,	  IL10RA	  in	  
very	  early	  onset	  IBD)	  on	  the	  left,	  while	  the	  complex	  disorders	  towards	  the	  
right	  side	  are	  thought	  to	  arise	  predominantly	  from	  environmental	  
exposures	  interacting	  with	  several	  genetic	  factors.	  	  
 
1.3 	  Inflammatory	  bowel	  disease	  
IBD are disorders characterized by chronic/ relapsing intestinal inflammation thought 
to arise as an inappropriate immunological response to microbial or other 
environmental exposures in a genetically susceptible host.21 Ulcerative colitis (UC), 
which is restricted to the colon and CD, which can affect any segment of the 





IBD typically presents in early adulthood with prospects of considerable lifetime 
morbidity.42, 43 Diarrhoea, malabsorption, anaemia and abdominal pain are typical 
symptoms of IBD. The course of the disease, location, extent of inflammation and 
complications are still highly variable suggesting underlying differences in 
pathophysiological mechanisms. Patients with CD are particularly prone to acquire 
intestinal fibrotic strictures, fistulas or abscess formation with the need for surgery. 
Development of colorectal carcinoma, extraintestinal autoimmune phenomena such 
as arthritis, uveitis, liver disease and psoriasis are associated with both types of 
IBD.44, 45, 46 
Management of IBD relies on anti-inflammatory drugs, nutritional support and 
sometimes surgery. Biological treatments, e.g. antibodies directed towards tumor 
necrosis factor alpha (TNFα) or integrin α4β7, have revolutionized the treatment of 
IBD, but still lack of response, loss of response and concern about long-term side 
effects call for better understanding of disease mechanisms and novel treatment 
strategies.47, 48  
A rising incidence of IBD in industrialised countries during the last decades suggests 
that life style changes and environmental exposures are important for disease 
initiation.14 A role of dietary factors is also indicated by the therapeutic response 
found in many paediatric CD patients treated with exclusive enteral nutrition.49 Long-
term exclusive intake of a nutritional formula is poorly tolerated and there is an 
increasing interest as to whether other means of dietary modification (e.g. removal of 
causal factors) or oral therapies that modulate the intestinal microbiota hold clinical 
utility.50, 51  
1.3.1 	  Genetics	  of	  IBD	  	  
Familial aggregation of IBD is evident in the clinic as well as in epidemiological 
studies indicating that IBD is partially inheritable.42 Twin studies have estimated that 
heritability contributes to > 50% of the liability to CD and somewhat less to UC.52 
Many families affected by IBD participated in the earliest efforts to map the genetics 





method was dubbed IBD1.53 Further dissection of this locus revealed that the linkage 
is specific for CD and is explained by SNPs in the gene NOD2.54 55 
This landmark finding demonstrated that it is possible to detect genetic factors 
influencing the risk for development of IBD and other complex disorders. However 
the linkage study design is limited by the availability of families with a sufficient 
number of affected members and has proven inadequate when searching for genetic 
variants with low effect size.  
The focus thus switched to case-control studies, in which the genetic constitution of 
patients with IBD was compared to that in healthy unrelated controls. This design 
called genome-wide association study (GWAS) was facilitated by the microarray 
technology that allowed rapid and affordable methods to capture SNPs throughout the 
whole genome in a large number of participants.  
At the start of the present project the number of IBD associated genetic loci detected 
by GWAS approached 100, and with subsequent studies recruiting increasing number 
of participants the number now exceeds 200 with approximately half of the risk genes 
being shared between UC and CD.17, 56, 57 NOD2 remain the strongest association 
signal in CD. This gene encodes nucleotide oligomerization domain containing 2 
(NOD2), an intracellular receptor for bacterial wall patterns.54, 55 This finding, 
followed by functional studies of NOD2 supported the suspicion that CD is linked to 
sensing and response to intestinal bacteria.58  
Both IBD subtypes are associated with genes implicated in the innate and adaptive 
immune system as well as the intestinal mucosal barrier.  In UC the human leucocyte 
antigen (HLA) complex on chromosome 6 represents the strongest genetic 
association,59 which could imply that the colitis is an autoimmune response to a yet 
unknown antigen. This concept is supported by the continuous and relatively 
superficial distribution of UC.60 CD on the other hand tends to be discontinuous, 
more invasive and CD specific genetic risk is linked to impairment of bacterial 
sensing and autophagy, i.e. important factors in the maintenance of a gut barrier 





bacteria are found in mucosal specimens of CD patients, the concept of CD as a 
chronic infectious disorder is likely overly simplistic.64, 65 Furthermore, genetic 
studies have challenged the diagnostic distinctions under the IBD umbrella, 
suggesting that both CD and UC comprise several distinct disease entities 
representing a spectrum of underlying pathology.66, 67  
Key questions regarding the initiating factors in IBD and the role of genetics remain 
unanswered. The majority of the risk markers reside outside the coding parts of the 
genome and their implications for individual gene function remain to be clarified.68 
While increasing the number of participants in ever larger studies have provided 
power to discover new associations, a large gap still remains between the heritability 
estimated from epidemiological studies and the heritability explained by GWAS.68 
The “missing heritability” could partially be explained by rare genetic variants that 
are not captured by the association study design, but typically found in patients with 
severe phenotypes or with familial clustering of disease.21  
An association between familial diarrhoea and IBD had been reported in patients with 
congenital chloride diarrhoea, which is caused by loss-of-function variants in the 
anion exchanger gene SLC26A3.32 Interestingly common genetic variants in the same 
gene have been associated with risk for development of UC, suggesting that 
aberrations in this ion transporter might act in similar ways to increase susceptibility 
to IBD in the general population as in patients with inheritable diarrhoea.69, 70 That 
alterations of ion transport could shape the intestinal bacterial communities had been 
reported at the time of publication of paper I, but to our knowledge no studies had 
hypothesized this could be a potential driver of intestinal inflammation.71  
1.3.2 	  The	  intestinal	  microbiota	  	  
Large communities of bacteria, archaea, vira, fungi and protozoa, collectively 
referred to as microbiota, inhabit the human gut. Traditionally medicine has regarded 
microbes largely as potential troublemakers (e.g. Vibrio cholera, enterotoxigenic E. 
coli, Salmonella, Clostridium difficile etc.). Diarrhoea caused by Clostridium difficile 





microbiota, showing that our microbiota can also protect against illness.72 In fact the 
intestinal microbiota is now emerging as a new “organ” that serves its host by 
contributing to metabolism, immunity and nutrition.73  
The study of the interplay between the host and the microbiota has been greatly 
facilitated by the application of genetic methodology.74 New sequencing technology 
has made it possible to capture the totality of microbial genes (microbiome) of the 
gut, without depending on cultivating these organisms in the lab. The genes carried 
by the intestinal microbiota can tell us not only what species are present, but also 
what these microbes can do. The intestinal microbiome encode proteins involved in a 
large number of metabolic and other functions.75 This enables the microbiota for 
example to generate nutrients and immunologically active molecules (e.g. butyrate) 
from otherwise indigestible dietary fibers.76  
We use two basic terms regarding microbiota diversity. Alpha diversity denotes the 
richness of species within an individual (or sample). Beta-diversity is a measure of 
diversity between individuals/samples. While the composition of bacterial species is 
quite variable between healthy individuals the metabolic capacity of the intestinal 
microbiome is fairly similair.75   
Classification of the microbiota adopts the taxonomic principle, which places the 
organism in a hierarchic system (Figure 3). Today genetic overlap and discrepancy 
between microbes define their taxonomy, i.e. their relatedness, conceptualised by 
Darwin as branches in the “tree of life”, as a function of microbial evolution. 
Horizontal gene transfer between microorganisms defies the evolutionary tree of life 
concept and microbial taxonomy is therefore a knotty and evolving discipline.77   
The intestinal microbiota undergoes compositional changes from birth and onwards, 
partially depending on microbial exposure during delivery (caesarean section versus 
vaginal) and dietary factors (breastmilk versus formula, moment of weaning).78 From 
later childhood the intestinal microbiota remains fairly stable throughout life, but is 
responsive to dietary changes and use of antibiotics.73, 78, 79 Cell-wall polysaccharides 





may play a decisive role in immunological tuning of the gut and affect the fine 
balance between tolerance and responsiveness to commensal bacteria and thereby 
susceptibility to a range of diseases.80, 81, 82  
 
 
Figure 3: Taxonomy of E. coli and the common house mouse 
 
Apart from age and diet, the composition of the intestinal microbiota varies across 
geography and disease state. Loss of alpha-diversity is a prominent feature of several 
diseases, including morbid obesity, diabetes and IBD.16, 83, 84, 85 Interestingly this 
phenomenon is associated with the transition from a traditional, mainly plant based 
diet to a modern diet, dominated by a higher intake of simple sugars, fat and animal 
proteins as well as the increasing use of antibiotics.86, 87 Alterations in the intestinal 
microbiota have thus been proposed as an explanatory causal link between the 
modern life style and the rising prevalence of disorders such as IBD and diabetes.51, 85 
This hypothesis has been supported by animal and human studies including one 
showing that obese patients with the metabolic syndrome restored insulin-sensitivity 



























Faecalibacterium prausnitzii is a prominent beneficial and usually highly abundant 
bacterium of the gut. This bacterium contributes to the intestinal homeostasis by 
producing butyrate, a short chain fatty acid that nourishes the intestinal epithelium 
and regulates ion transport and inflammation.89, 90 Depletion of F. prausnitzii has 
consistently been demonstrated in the stools and mucosa of IBD patients,16 and is a 
predictor for relapse following surgery in CD patients.91 Various experiments support 
its role in protection against inflammation.92, 93 Still, this notion has been challenged 
by a trial showing persisting loss of F. prausnitzii and clinical improvement in 
paediatric CD patients treated with exclusive enteral nutrition.94  
Enrichment of the family Enterobacteriaceae is another characteristic of the 
compositional microbiota imbalances (dysbiosis) found in IBD.16 One important 
question is whether the dysbiosis contributes to initiate and sustain inflammation or 
whether it is only a result of inflammation.95 To this end it is of great interest to study 
the microbiota in individuals that are at genetic risk, but have not (yet) developed 
IBD.96  
Given its importance in health and disease and the complexity of the interaction 
between man and his/her intestinal microbiota, it is vital to further understand the 







2. Aim of project 
The project had 2 main aims, 
1. To identify genetic and clinical characteristics of a novel inheritable disorder. 
This comprised 3 subprojects described in paper 1. 
a. To find the chromosomal region where a causal genetic variant was 
residing, and by sequencing of this region to discover the variant. 
b. To study the biological effects of the identified variant in a cell-model. 
c. To gather and systematise clinical information about the patients.  
 
2. To look at possible biological underpinnings of the disease manifestations, 
focusing on the intestinal inflammation. This aim included 4 subprojects: 
a. To test whether the gene discovered in paper I and other genes implicated 
in the pertinent biological pathway are enriched in GWAS of IBD. 
b. To interrogate whether known genetic IBD risk variants relate to clinical 
manifestations of the disorder. 
c. To characterise the global gene expression in distal small bowel of patients 
compared to healthy controls and to unrelated patients with IBD.  
d. To characterise the intestinal microbiota in patients, compared to related 






3.  Methodological considerations 
3.1 	  Overview	  and	  study	  design	  
Paper I 
We used genetic linkage analysis to search for the genetic cause of a presumably 
novel inheritable diarrheal disorder. Following identification of a genetic region 
linked to disease status, we searched for a candidate genetic variant using DNA 
sequencing. Any rare genetic variants discovered after sequencing were evaluated as 
to their pathogenic potential and lastly functionally tested in a cell-model using site-
directed mutagenesis.  
 
The concept of genetic linkage analysis is that disease-causing variants tend to be 
inherited (linked) together with other genetic markers residing nearby on the same 
chromosome. After typing markers across the whole genome in each participant, 
biostatistics tools aggregate information from these markers, how participants are 
related and disease status to identify the genomic region most likely containing the 
causative genetic change. For detection of previously unknown rare variants and their 
pathogenic potential, the sequence data were compared with reference DNA 
sequences in humans as well as in other species using different bioinformatics tools 
(see Table 4). 
 
The choice of using linkage analysis seemed reasonable because the high number of 
affected individuals in the pedigree provided robust statistical power, and also due to 
the relative low cost of microarray SNP mapping.97 An alternative approach, is to 
sequence the whole genome (WGS) or only its protein encoding part (whole exome 
sequencing/WES) and look for rare variants segregating with disease status. Here 
sequencing and evaluation of rare variants however easily become more extensive, 
and the overall project potentially more costly and time consuming.97, 98  







This paper reports 3 different experiments aiming at elucidating a molecular link 
between GC-C activation and development of IBD. 
 
1) We hypothesised that common variants in genes participating in the GC-C 
pathway may contribute to development of IBD. Therefore, we used gene set 
enrichment analysis (GSEA) to test whether a set of genes in this pathway was 
over-represented (enriched) in the top end of the association statistics from 
publicly available IBD GWAS.99 Although several limitations apply regarding the 
interpretation of GSEA in GWAS data, the method is valuable to detect the 
accumulated effect of genetic variants that individually might be too weak to pass 
the threshold for genome-wide significance (defined as P<10-8).100 101, 102  
2) We then evaluated whether IBD genetic risk variants (as previously identified in 
GWAS) impact on development of IBD in FGDS patients. This was an 
exploratory study, where genotypes of IBD affected and non-affected FGDS 
patients were compared taking into account various possible modes of 
inheritance.39  
3) Finally, we performed a hypothesis-free experiment of gene expression in the 
distal small bowel from biopsies of FGDS patients compared to healthy controls 
and to disease controls with CD. The aim was to identify molecules that could 
point to biological pathways potentially involved in the pathogenesis. Biopsies 
from the distal small bowel were chosen since this is the predilection site for 
inflammation in FGDS patients with concomitant IBD. Inference about cause and 
effect is limited in a cross-sectional study design compared to prospective studies 
(e.g. studying patients before and after development of a certain complication). 
However, using microarrays we could evaluate the difference in transcription of  
> 25,000 genes between the different groups. We used quantitative polymerase 
chain reaction (qPCR) as a complimentary method to more accurately quantify 





immunohistochemistry to evaluate qualitatively whether transcriptional changes 
also were evident at the protein level. 
 
Paper III 
This project was a cross-sectional study of the intestinal microbiota in FGDS patients 
compared to unrelated IBD patients, as well as related and unrelated healthy controls. 
The aim was to characterise the impact of GC-C activation on the intestinal 
microbiota. We chose to use 16S rRNA gene sequencing of faecal samples because 
this is a well-established method, which provides good coverage of different types of 
bacteria. By targeting only the 16S rRNA marker gene, it limits the sequencing load 
and costs.103 The more expensive, time- and computer-intensive alternative, 
“shotgun” sequencing can provide data on the full microbial genome (microbiome), 
add information about its functional properties and give a better resolution of 
particular bacterial species, but none of these advantages were considered crucial as a 
first step to clarify whether changes could be detected at all.  
We primarily tested the hypothesis that GUCY2C mutations constitute an inheritable 
factor influencing the intestinal microbiota. Secondarily, we examined whether 
findings in FGDS patients aligned with published reports on gut microbiota involved 
in intestinal inflammation and whether findings in FGDS with IBD were similar to 
those found in conventional IBD patients 
.  
Most samples were sequenced three times (according to two different amplification 
protocols and in two institutions) allowing us to control for technical and 
methodological biases. Stool samples from healthy familial controls (without FGDS) 
were collected to assess potential confounding effects of geographics, other genetic 
factors and nutritional habits of the family.79, 104 	  
3.2 	  Selection	  of	  participants	  and	  clinical	  data	  
The papers constituting this thesis report clinical data that are predominantly cross-





FGDS patients have been evaluated regularly from 2012. This follow up has helped 
us to update clinical data as needed and ensured real-time observations of FGDS 
patients experiencing complications, e.g. intestinal obstructions needing surgery.  
 
Paper I 
Accurate assignment (affected or not affected) of participants is important when 
searching for disease causing variants in genetic linkage analysis. Even if the familial 
diarrhoea appeared to be inherited in an autosomal dominant pattern, we could not 
know in advance whether the segregation of the trait (diarrhoea) perfectly aligned 
with the underlying causative genetic variant we were searching for. The trait could 
have appeared at later age in the apparently healthy relatives (late penetrance) or only 
in a subset of mutation carriers (partial penetrance). Accordingly in the linkage 
analysis only adult family members were included in the group classified as 
unaffected.  
The patients with familial diarrhoea as included in paper I were members of three 
branches (A, B and C) of a large family (Figure 4), and two of these branches (A and 
B) were studied independently before we realised that they belong to the same 
kindred and carry the same mutation. Since branches B and C were discovered later 
(by the author of this thesis), only patients in branch A were included in the initial 









Figure 4: Pedigree of the large family studied in this project. Filled circles 
(females) and boxes (males) mark individuals affected by diarrhoea, and 
red filling marks individuals that are also diagnosed with inflammatory 
bowel disease (IBD). There are three main branches (A, B and C) in the 
family.  
 
All affected family members contributed with clinical information of help to outline 
the variable complications associated with carrier status of the disease causing 
genetic variant. This information was obtained during systematic clinical 
consultations, questionnaires, review of clinical records and lab results. We 
performed further investigations such as radiology and hydrogen-breath tests in some 
of the patients. 
 
We used the Rome 2 questionnaire (Table 2 and Appendix 1) validated for 
functional abdominal disorders from patients and healthy relatives alike. This choice 
was based on the experience that symptoms (e.g. intestinal gas, loose stools, 
































Table 2. Questionnaires and scoring systems used in the thesis 
 What it is:  Where used: 
Rome 2  Self reported symptom scoring used to 
diagnose and classify functional 
abdominal disorders. 
Adult family 
members, paper I 
GSRS Self reported abdominal symptom score, 






Self reported habitual intake of >200 
food items 
FGDS and healthy 
relatives, paper III 
Harvey-Bradshaw 
Index (HBI) 
Disease activity score in CD based on 
objective findings and reported 
symptoms 





Disease activity score in UC based on 
objective findings and reported 
symptoms 






Publicly available IBD genetic case-control association (GWAS) data 
The first experiment in paper II used publicly available datasets obtained in GWAS 
performed by a consortium of groups, representing in total 12,882 IBD cases and 
21,770 healthy controls.17 Our project did not contribute to collection of these data. 
We used the summary statistics for association analysis of the genetic markers. All 
participants were of European descent, and since IBD is more prevalent in certain 
populations and tend to run in families, the data had undergone some degree of 
control for population stratification and close relatives had been removed. IBD was 
represented by CD, UC, as well as the combined data from both entities, there were 
thus three datasets available for our analysis. Since FGDS patients had been 
diagnosed with CD, and the GC-C animal models colitis we chose to use all three 








IBD-risk variants in FGDS 
In paper II we assessed known IBD genetic risk variants in FGDS, hypothesising that 
development of CD in FDGS patients could be explained by a higher burden of IBD-
genetic risk variants. The median age of onset of CD in the population as well as in 
FGDS is ~30 years and we chose this as the lower age-limit for inclusion in the 
control group to represent FGDS patients without IBD.42 FGDS patients were 
grouped as CD affected when fulfilling both of the following criteria:  
1) A history of clinical suspicion of CD, supported by endoscopy findings.  
2) A history of treatment for CD or ileitis 
This classification differs from standard IBD diagnostic criteria by not requiring 
histopathological examination obtained by biopsies.105 On the other hand using 
standard criteria would have resulted in exclusion of two patients who had been 
treated for IBD, but for whom histopathology specimens were lacking.  
 
Gene expression in ileal mucosa 
All FGDS patients in branch A (Figure 4) were invited to participate in the study of 
gene expression in the distal small bowel. This involved investigation with 
ileocolonoscopy, which is an invasive and sometimes unpleasant endoscopic 
procedure. Several of the FGDS patients had already undergone this investigation at 
least one time before the study. After recruiting the first eight patients we decided 
that further inclusion should be restricted to situations where ilecolonoscopy was 
considered helpful for clinical decision-making, e.g. to rule out or monitor IBD.  
Additional four mutation carriers were investigated with ileocolonoscopy in the study 
period, and three of these were included in the study.  
 
Healthy controls had been recruited for an unrelated project by advertisement and a 
financial compensation to perform the procedure, and absence of gastrointestinal 
symptoms was the main inclusion criterion. Individuals that volunteer for such 
studies may differ systematically from cases e.g. regarding lifestyles that could 





in healthy controls than in FGDS patients.106 For the sake of our own reassurance, we 
therefore performed an exploratory analysis (not commented or shown in paper II) 
excluding smokers and validated the main results shown in paper II. Healthy family 
members might generally be motivated to contribute to increase knowledge about 
health problems affecting close relatives and would arguably have constituted the 
ideal control group. However, these advantages were outweighed by the availability 
of the above mentioned biopsies, and we found it not to be ethically compliant to 
expose these healthy relatives to endoscopy.  
 
The unrelated CD patients were recruited from the outpatient clinic at Ullevål 
University Hospital, which provide tertiary- and secondary-level health services. In 
order to minimize the contribution of inflammation to the gene expression profile, 
normal histology, was made a selection criterion for the unrelated CD patients.  
Paper III 
Collection of microbiota samples in patients and controls 
We invited all FGDS patients regardless of age to participate in the study of the 
intestinal microbiota. Since the number of children was low and age is associated 
with the gut microbiota composition, participants below 15 years of age were 
excluded.87 All adult healthy family members were invited to participate as one of the 
control groups in the study, intending to take advantage of their quality of matching 
FGDS in many aspects relevant for gut ecology such as genetics (apart from the 
disease causing variant), household factors, nutrition and geography.79, 104, 107  
We also included a larger group of unrelated healthy controls recruited from the 
Norwegian Bone Marrow registry.  
 
Using individuals that have volunteered as bone-marrow donors as a healthy control 
group holds the advantage that they had been screened for diseases and are generally 
considered healthy. Still, health issues that can influence the intestinal microbiota, 
could theoretically have arisen for certain individuals after inclusion in the registry 






Antibiotic use and nutrition influence the intestinal microbiota, so we excluded all 
samples taken within 4 weeks of antibiotic treatment and participants reporting 
special diets (e.g. cow milk-free, gluten-free, vegan).  
 
Collection of other variables in participants 
In order to assess whether FGDS patients share food preferences with their relatives 
and the potential impact of nutritional habits on observed changes in the gut 
microbiota, we obtained so-called “food frequency questionnaires” from these two 
groups. The food frequency questionnaire, validated for use in the Norwegian 
population, inquires about the habitual intake of a large list of commonly used food 
items.108 This information is extracted and converted to estimates of intakes of 
various macro- and micro-nutrients (e.g. energy, fat, carbohydrates, proteins, fibre, 
added sugar, alcohol). The reporting is liable to systematic biases (e.g. underreporting 
the total amount of food and/or specific items perceived to be “unhealthy”), and in an 
attempt to minimize such bias we normalized measurements to total energy intake.109  
 
While 24-hours food recall or 4-days food registration may outperform food 
frequency questionnaires when assessing the food intake on short term, the latter is 
considered better suited to define food habits and thus nutrients that could influence 
intestinal microbiota over time, e.g fibre.110, 111 We calculated the basal metabolic rate 
(BMR) according to weight, age, and gender,112 in order to estimate the rate of 
obvious underreporting.108 
 
We used the GSRS (gastrointestinal symptom rate scale, see Table 2 and Appendix 
2) questionnaire to record symptoms in paper III.113  
 
FGDS patients were stratified for IBD status using the same criteria as in the study of 
IBD risk variants in paper II. Furthermore, we included stool samples from unrelated 
IBD patients from the outpatient clinic of Oslo University Hospital Ullevål. The same 





intestinal inflammation, we used clinical disease activity scores (Harvey Bradshaw 
Index (HBI) and the Simple Clinical Colitis Activity Index (SCCAI) in CD and UC 
respectively) and calprotectin as a stool marker of intestinal inflammation. 114, 115, 116  
 
3.3 Sample	  collection,	  preparation	  and	  storage	  
DNA isolation 
Human DNA used for mapping SNPs, sequencing and IBD-risk variant genotyping in 
paper I and paper II was isolated from whole blood using a standard procedure that 
combined mechanical, chemical and electromagnetic extraction.117 
 
RNA isolation from small bowel biopsies 
The transcript of genes, RNA, shows variation throughout the day, across different 
tissues and cells, in response to environmental exposures and disease states, and can 
easily be altered during the sampling procedures due to degradation (e.g. by RNases). 
106, 118, 119 All tissue samples were obtained during endoscopy after an overnight fast. 
In order to prevent degradation, we preserved the biopsies immediately in fluid 
nitrogen at -80˚C. We extracted total RNA was in presence of an RNase inhibitor 
after thawing and physical disruption of biopsies. RNA extraction followed a 
standard method and was performed simultaneously in all patient and control 
materials.117, 120 The RNA was amplified and reversely transcribed to complimentary 
RNA (cRNA), and then biotin-labelled. We checked the amount and purity of RNA 
by electrophoresis and photospectrometry. Three samples (two healthy controls and 
one CD) were excluded due to low RNA-integrity.  
 
Changes in cell composition following proliferation, differentiation or recruitment of 
certain cells e.g. due to inflammation can contribute to gene transcript differences 
when comparing two disease states.19 A standard approach to this issue, which we 
adopted, is to obtain and examine qualitatively an adjacent biopsy in light 





stained and evaluated according to standards used in clinical practice. The histology 
samples were then used to examine whether particular changes of gene expression 
were also observed at the protein level as assessed by immunohistochemistry (see 
below).  
 
DNA isolation from stool samples 
The composition of the cell-wall differs substantially among prokaryotic organisms, 
e.g. thick in gram-positive bacteria such as Actinobacteria and Firmicutes, thin in 
gram-negative bacteria such as Enterobacteriaceae. The choice of extraction method 
may thus impact on retrieval of DNA of the respective taxa.117, 122  
Different taxa may show variable degree of survival and proliferation following 
sampling, and immediate analysis of fresh stool samples may be considered ideal in 
microbiota studies,103 but with most participants living distant from the laboratory 
this was not practicable. We provided the participants with a collection device and 
stool collection tubes (Stratec Molecular GmbH, Berlin, Germany) containing 
reagents specifically designed for preservation and subsequent extraction of DNA for 
sampling at home and instant expedition by mail. 123, 124 In accordance with the 
manufacturer instructions, specimens arriving the laboratory more than 72 hours after 
sampling were excluded. Specimens were frozen at a maximum temperature of -20˚C 
upon arrival.   
 
All subsequent DNA extraction was done at a single laboratory bench with careful 
attention to hygiene in order to avoid contamination and degradation of samples.  
DNA extraction protocols used for prokaryotic DNA usually employ chemical, 
mechanical and thermal methods.122 In our study, we used the PSP Spin Stool DNA 
Kit method (Stratec Molecular GmbH, Berlin, Germany), which combine thorough 
homogenisation, enzymatic protein digestion at 80º C and zirconium bead beating 
followed by removal of substances that could inhibit subsequent PCR-amplification 





3.4 	  Sequence	  analyses	  of	  DNA	  and	  RNA	  
Availability of robust methods to determine the order (sequence) of DNA and RNA 
was a prerequisite for the current project, and several have been employed, as 
outlined in Table 3.  
Table 3. Methods used for determination of DNA or RNA sequences in this project 




Linkage analysis (1) 
   
Variant-detection    (2) 
IBD genetic risk variants 
in FGDS 
(3) 
   
Gene expression (4) 
   
Microbiota 
   
(5) 
Throughput Intermediate Low Low High 
Detect new variants No No Yes Yes 




1) GeneChip Human Mapping 250K NspI array (Affymetrix Inc., Santa Clara, CA, USA) 
1) Human Mapping 250K NspI Array (Affymetrix, Santa Clara, USA) 
2) Illumina HiSeq (Illumina Inc., San Diego, CA, USA) 
3) The “Immunochip”, Illumina iSelect HD custom genotyping array  
4) Illumina HT12 v4 Bead Chip 
5) Illumina MiSeq (performed with 2 alternative library protocols, at 2 independent institutions) 
 
Table 3 We used 4 in principle different methods (columns 2-5) to obtain nucleotide 
sequence data in this project. The chosen methodology is marked with a shaded 
area for 5 subprojects (rows 3-7). Apart from microarray SNP mapping employed in 
linkage analysis, technical validation using complimentary methods was performed 
in all subprojects.    







A common feature of the microarrays used in this project is that they provide a spatial 
arrangement (array) of probes designed to capture sample DNA/RNA by 
hybridization. The annealing of sample to probe is registered as a fluorescent signal 
emitted from the respective positions on the microarray upon excitation with laser.  
 
Mapping genetic markers for linkage analysis 
Genetic markers used for tracking monogenic inheritance with linkage analysis 
should show appreciable variation between individuals and be distributed throughout 
the whole genome with intervals short enough to minimize recombination between 
the unknown mutation and the nearest markers. SNPs fulfil these criteria, and have 
replaced other types of markers previously used in linkage analysis.53 125 We chose to 
map SNPs for linkage analysis in paper I using microarrays covering a modest 
number of SNPs (~250,000).  
 
The SNP microarray is designed with clusters of oligonucleotide sequences (probes) 
selected for being complimentary to sequences containing SNPs, imprinted in defined 
positions on a glass surface. Sample DNA is applied after it has been fractioned into 
shorter sequences and labelled with a substance able to emit a fluorescent signal. 
Hybridizing to respective probes subsequently captures sample sequences. A scanner 
reads the pattern and intensity of fluorescent signals from the sample sequences on 
the microarray, and using bioinformatics tools (see Table 4) these are converted to 
information about the genotype, (e.g. C/C, C/T or T/T) for each SNP position.  
 
Genotyping IBD-risk variants in patients with FGDS 
We chose to genotype the current (2012) top IBD-associations, representing 163 
genetic loci, and to perform full sequencing of the NOD2 gene.68 Genotyping was 
performed using the Immunochip (Illumina Inc., San Diego, USA). The probe design 
of this microarray provides high-density SNP coverage in genetic regions implicated 





126 The Immunochip is conceptually similar to the microarray used in genetic linkage 
analysis, but allows much more narrow spacing of probes.127  
Gene expression by microarrays 
Gene expression microarrays can be used to detect and quantify a comprehensive 
selection of gene transcripts (RNA sequences) in a single experiment.119 Massively 
parallel RNA-sequencing provides deeper coverage of transcripts (e.g. better ability 
to capture sequence variation and a broader dynamic range for quantifying gene 
expression), but this alternative was discarded partly due to the higher costs.119 Subtle 
signal differences between microarrays might introduce a technical bias in gene 
expression studies. This was one important reason that we chose to use the bead chip 
technology described above (Illumina HT12 v4 bead chip, Illumina Inc., San Diego, 
USA), which allow 12 samples to be analysed on one chip. This microarray capture 
47,000 different RNA sequences, covering most protein encoding as well as a large 
number of non-coding transcripts. In order to minimize batch effects we assured that 
samples from FGDS, healthy controls and unrelated CD patients were all evenly 
represented on each chip.  
Processing of microarray data  
Control for systematic variations between chips regarding signal intensities is 
recommended, and this possible source of bias was addressed by normalising 
expression values according to mean within the respective inter-array quantile.128 
Correspondence analysis can reduce complex data to a minimum of two dimensions, 
of help to visualize trends in the data.129 Our correspondence analysis of the data did 
not show deviating samples or batch effects related to the equipment or the RNA- 
amplification procedure. During the first steps of microarray data processing, we used 
the GenomeStudio Data Analysis Software (Illumina, Inc., San Diego, USA). We 
used the freely available Jexpress2012-tool (Jexpress.bioinfo.no) developed at Bergen 






3.4.2 	  Quantitative	  PCR	  and	  immunohistochemistry	  
Polymerase Chain Reaction (PCR)  
In paper I we used PCR to selectively increase the amount of the GUCY2C gene, and 
in paper III to amplify the prokaryotic 16S rRNA gene (Figure 3). Amplification of a 
target nucleotide sequence by PCR requires a polymerase enzyme, a template (single 
stranded DNA), free nucleotides, and a primer pair (flanking each end of the target 
nucleotide sequence). 
Quantitative PCR 
In paper II we used quantitative PCR (qPCR) to measure and verify relative changes 
of genes highlighted by the gene expression microarrays.  In qPCR the yield of each 
PCR cycle is measured as the intensity of fluorescence emitted by labelled probes 
when digested by the polymerase. The number of cycles necessary to reach a certain 
signal threshold thus gives information about the target gene quantity in each sample. 
Target gene quantities can be normalised against genes that are constitutively and 
thus evenly expressed throughout the samples in order to control for differences 
across samples regarding the yield of RNA extraction, reverse transcription and 
amplification.131, 132 As a control gene we used ACTB, which displayed an even 
expression profile across the groups as evaluated visually and statistically in the 
microarray data. Subtle variation in control gene expression could still impact on the 
results and we therefore validated all findings using a second control gene (B2M).  
Immunohistochemistry 
We used hmmunhistochemistry (IHC) to assess whether differentially expressed 
genes also translated to altered levels of the respective proteins in small bowel 
biopsies.133 Slides embedded in paraffin maintain tissue architecture and can thereby 
show where changes are taking place and which cell types are affected. During the 
IHC procedure, histology slides were exposed to monoclonal mouse anti-
metallothionein (the primary antibody), and stained using the ultraView Universal 
DAB Detection Kit and the BenchMark Ultra immunohistochemistry/in situ 





analysed tissue architecture as well as immunostaining of the tissues using qualitative 
assessments.133  
 
3.4.3 	  DNA	  sequencing	  of	  GUCY2C	  and	  NOD2	  	  
Sanger sequencing 
Genetic linkage analysis performed in paper I identified a candidate region spanning 
28 protein-encoding genes.  Our suspicion was early on targeted at GUCY2C, due to 
its role in infectious diarrhoea. In sequencing the exomes of GUCY2C, we chose to 
use a current version of the chain termination principle, also known as Sanger 
sequencing.134 Amplification of target sequences (here GUCY2C exomes) by PCR 
was performed in a mix of normal nucleotides (deoxyribonucleotides) and 
nucleotides chemically modulated to terminate the nucleotide chain 
(dideoxyribonucleotides). Each of the four different dideoxyribonucleotides were 
provided with a specific fluorescent dye. The target sequence was resolved by 
aligning the dye-tags according to information about the length of the respective 
copies, as determined by capillary electrophoresis and fluorescence detection. This 
method was also used to sequence the NOD2 exomes in paper II. 
Sequence variant analysis tools-bioinformatics 
The raw (unprocessed) data generated from microarrays and other types of 
sequencing need extensive processing before they can give us biological knowledge. 
Computer technology allows fast analysis of large datasets, aided by software able to 
integrate existent knowledge stored in databases, with mathematical and statistical 
procedures. This field of science called bioinformatics, has become a prerequisite for 
genomic research. During this project we used a number of bioinformatics tools as 
outlined in Table 4. For example we used CASAVA (Illumina Inc., San Diego, USA) 
and GenomeStudio (Illumina) to perform data quality-control in paper I and II.135 We 
used various tools to align sequence data (reads) and map these to the human 
reference genome,136, 137 and to discover and evaluate (annotate) variants (see Table 





knowledge database NCBI human db SNP database, and was used to evaluate 
whether variants detected had previously been reported.  
Whether any genetic variant would change the amino-acid sequence in the respective 
protein is another important clue as to its potential to alter gene function and cause 
disease. For the latter assessment, we used a tool that predicts protein-structure from 
amino-acid sequence and compares the amino-acid sequence of a particular protein 
across many species (Annovar, www.annovar.openbioinformatics.org).138Genetic 
variants that lead to changes in amino acid are more likely to be detrimental if the 
amino acid for the given position has remained unchanged throughout evolution, in 
other words the same in many species. To prove how and whether a genetic variant 
truly affects protein function may however require testing in a genetically modified 

















Table 4. Bioinformatics tools and databases used in the project 
 
Allegro deCode Genetics, Reykjavik, Iceland  Software for genetic linkage analysis.                                                                           
 
Annovar www.annovar.openbioinformatics.org  Software and knowledge database for evaluation of genetic 
variants. 
 Burrows-Wheeler transform Data compression algorithm e.g. used when aligning sequence 
data against a reference genome. 




DAVID National Cancer Institute, Frederick, USA 
 
Software for statistical analysis of microarray data on various 
knowledge databases.  
FLASH Johns Hopkins Medicine, Baltimore, USA 
 
 
Software for aligning DNA/ RNA sequences generated by the 
paired-end procedure.  
 GeneCards Weizmann Institute of Science, Rehovot, Israel 
 
Knowledge database of genes with information e.g. about their 
function.  
  GeneOntology www.geneontology.org 
 
 
Knowledge database of genes and their functions, products and 
interactions. 
Genome analysis tool kit Broad Institute, 
Boston, USA 
 
Algorithms for analysing DNA and RNA sequence data, e.g. 
variant detection.  
GenomeStudio Illumina Inc., San Diego, USA  Tool for processing and quality control raw sequence data e.g. 
from microarrays. 
GreenGenes www.greengenes.secondgenome.com 
   
Database of 16S rRNA sequence variation in bacteria. 
Gene set enrichment analysis/GSEA 
Broad Institute, Boston, USA 
  
A variant of statistical enrichment analysis in genomic data. 
GraphPad Prism GraphPad Software, San Diego, 
USA 
 
Software for basic statistics. 
Ingenuity Pathway Analysis Qiagen, Hilden, 
Germany
  
Software and knowledge database for pathway analysis in 
genetics. 
J-EXPRESS 2012 University of Bergen, Norway 
 
Software for processing and statistical analyses of gene 
expression data. 
LDsnpR University of Bergen, Norway 
 
 
Algorithm for assigning SNPs to genes based on location and 
linkage disequilibrium. 
LEfSE Harvard University, Boston, USA 
  
 
Statistical tool for analysis and visualisation of microbiota data.  
MaAsLin Harvard University, Boston, USA   
 
Statistical tool for controlling co-variables (linear regression) in 
microbiota analyses.  
NCBI human db SNP database National 
Center for Biotechnology Information, Bethesda, USA 
 
 
Database of known human genetic variants (SNPs). 
Oligo National Bioscience, Plymouth, USA 
 
Software for designing primers e.g. for amplification of exomes. 
Picard www.sourceforge.net 
 
Algorithm for manipulating high-throughput sequence data e.g. 
remove PCR duplicates. 
QIIME www.qiime.org 
  
Software package that integrate several bioinformatic tools in a 




Programming language developed for statistical analysis. 




Reference genome database. 
SAMtools www.sourceforge.net  Algorithms for transforming and storing sequence data e.g. into 
appropriate file formats.   
Seqscape ABI, Foster City, USA 
 
Software for analysing sequence data, against reference 
sequences.  
SPSS IBM, New York, USA 
 
 






3.4.4 	  DNA	  sequencing	  of	  the	  intestinal	  microbiota	  
Our study of the intestinal microbiota in FGDS was limited to focus on bacteria and 
archaea, in terms of composition and diversity. For this purpose, we chose to perform 
targeted sequencing of the prokaryotic 16S rRNA gene. This gene has nine hyper-
variable regions (V1-V9) (Figure 3, panel A) that show considerable sequence 
variation between different types of bacteria and archaea, and is thus a versatile 
marker of bacterial taxonomy.  Considering that the length of each sequence (read) 
generated by current technologies is restricted, one must select which 16S rRNA 
hyper-variable region to sequence. This choice may introduce a bias, since the 
selected region may not show the necessary degree of variation to allow detection of 
certain taxa.103 Addressing this issue we analysed our samples by two library 
preparation procedures, differing in regard to the 16S rRNA coverage.  
Library preparation 
In order to selectively increase sample 16S rRNA DNA for sequencing, PCR was 
used with primers flanking the relevant hyper-variable region. We created two 
collections (libraries) of sample DNA using primers flanking V3 –V4 (Figure 5) and 













 Figure 5   
A: Conceptual illustration of 16S 
rRNA, with regions that have 
same (black) nucleotide 
sequence across different types 
of bacteria, but variable (grey) in 
9 regions (V1-V9) of use as a 
marker of bacterial taxonomy. 
B: The primer design used to 
amplify the 16S rRNA V3-V4 in 
the microbiota samples. Adapted 
from and with permission from 
Martin Kummen, thesis (“Primary 
Sclerosing Cholangitis and the 
intestinal microbiota” 2016) 
Upon denaturation of DNA into 2 
strands, the target sequence (V3-
V4) is amplified using PCR with 
specifically designed primers.The 
primers used each contain 5 
elements: 
Genetic primers: targeting the 
conserved flanking regions of the 
hypervariable region of interest, 
for the forward and reverse 
primer, respectively. Linkers: 
selected to avoid homology with 
16S sequences in a reference 
database. Pads: used to adjust 
the estimated melting 
temperature of the total 
sequence. Index regions: each 
combination in the forward and 
reverse primer is unique for each, 
serving as an identifier showing 
what sample the read originates 
from.Adapter sequences: these 
are designed to ensure that the 
fragments adhere to the flow-cell 























Library of V3-V4 sequences
A
B 16S rRNA gene amplification 
V3 V4
Denaturation








Sequencing-by-synthesis (reversible-chain-termination) sequencing  
We used sequencing-by-synthesis to sequence the 16S rRNA gene. This is one of the 
most popular principles of massively parallel sequencing and was also used for 
validation of the GUCY2C exome sequencing in paper I during the review process. 
Fragments of the target DNA are hybridised to oligonucleotides on a flow-cell and 
then amplified into clusters each containing approximately 1,000 copies of each 
fragment. To the flow cell are then added a mixture of single nucleotides chemically 
modified to block the 3´end and to emit a base-specific fluorescent signal upon 
ligation.140, 141 A photo of the chip is taken and read by a scanner detecting which 
bases have been added at given positions. Next the unincorporated nucleotides are 
removed, 3´-ends chemically de-blocked and another cycle can start. While 
comparatively accurate, sequencing errors are prone to occur especially at the 
beginning and the end of the reads. However correct alignment of reads into longer 
sequences (contigs) is helped by many (parallel) reads generated for any nucleotide 
sequence, and by paired-end reads.142  
Samples were sequenced on the Illumina MiSeq platform at the Norwegian 
Sequencing Center, Oslo. In order to validate our methods and assess the impact of 
primer choice we generated and sequenced V4 specific libraries in all FGDS, healthy 
relatives and a large subset of the unrelated healthy and IBD controls. DNA extracts 
from the same samples were also sent for library construction and sequencing 
according to the same protocol at an external institution (Broad Institute, Boston, 
USA).  While we as expected observed an influence of primer choice on retrieval of 
certain taxa, we were able to validate V3-V4 findings in V4 data from both 
institutions.  
Furthermore we compared duplicate stool samples provided by FGDS and healthy 
relatives with at least one week interval showing high reproducibility and stability 






Figure 6. Consistency of data from duplicate samples. Illustration of 
beta diversity based on unweighted UNIFRAC- distances showing highly 
similar bacterial profiles (r2=0.92, P<0.001) in the same individual across 2 
samples (provided with at least one week interval). Samples from one 
individual are connected with a straight line. The illustration also shows that 
FGDS (in red) differ from healthy relatives (in blue).     
 
Microbiota data processing with bioinformatics  
 
While the human reference genome serves as a scaffold of help to assemble human 
sequence data, 16S rRNA sequence data in microbiota studies typically originate 
from a large number of species, and sequence data are evaluated against reference 
data that may be incomplete or still even erroneous for some taxa, e.g. by 
misalignment of sequences that originated from two different species into a hybrid 
(chimeric) sequence.143 We used the Quantitative Insights Into Microbial Ecology 
(QIIME) bioinformatics pipeline, which integrates tools for the analytical steps, 
including processing raw data, quality control, sequence assembly, taxonomic 
























data to microbial taxonomy and minimize errors e.g. due to chimera, we mapped 
reads against the16S rRNA reference sequence database GreenGenes.143 Here we 
assigned sequence data to operational taxonomic units (OTUs), which represent 
clusters with 97 % sequence similarity retrieved from the GreenGenes database and 
are thus proxies of actual microbial taxa. The OTUs are the principal units for further 
analyses. 
 
The number of mapped reads may vary across samples and if critically low, the 
within-sample diversity (alpha-diversity) may be poorly captured, and the sample 
might need to be discarded (cut-off at 8,750 in our data).  
	  
3.4.5 	  Functional	  analysis	  of	  the	  GUCY2C	  mutation	  	  
Site-directed mutagenesis 
Based on the symptoms of the patients, we suspected a gain-of-function effect, and 
we settled cooperation with a scientific group led by prof. Visweswariah at the Indian 
Institute of Science, Bangalore, India that had established methods to study mutated 
GUCY2C in a cell-model.147, 148 Complementary DNA of the GUCY2C variant was 
cloned into the mammalian expression vector pcDNA3, and together with non-mutant 
DNA transfected into HEK293 cells in order to study and compare the function of the 
mutant and the normal (wild-type) GC-C protein.  
3.4.6 Manual	  curation	  of	  GC-­‐C	  pathway	  gene	  set	  
For our analysis of IBD GWAS data in paper II we curated a gene set, aiming to 
capture the most important regulators of intestinal fluid shifts related to GC-C and 
CFTR signalling. We identified relevant genes using the search terms ”guanylate 
cyclase C” and ”CFTR” in Pubmed and GeneCards. The pathway is illustrated in 
Figure 7. While gene selection was validated using the Ingenuity database 
(https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/), the 





and dependent on prior knowledge on gene function. This is an inherent limitation 
pertaining to grouping genes according to their function, and must be kept in mind 
when interpreting the results in paper II.149  
 
 
Figure 7 The GC-C – CFTR pathway  
Illustration of guanylate cyclase C, cystic fibrosis transmembrane 
conductance regulator and interacting molecules that influence intestinal 
efflux of chloride (Cl-), sodium (Na+), bicarbonate (HCO3-) and water. 
(Adapted from figure 1, paper I 150 and Kato A et al. 151) 
(c)AMP; (cyclic) adenosine monophosphate, AMPK; AMP-activated protein 
kinase, CFTR; cystic fibrosis transmembrane conductance regulator, GC-C; 
Guanylate cyclase C, DRA; Down-Regulated-in-Adenoma (encoded by 
SLC26A3), (c)GMP; (cyclic) guanosine monophosphate, NHE;sodium-
hydrogen exchanger, NHERF; NHE Regulatory Factor, PDE; 
phosphodiesterase, PKA; protein kinase A, PKGII; cGMP-dependent 
protein kinase   






3.5.1 	  Basic	  statistical	  tests	  
For comparisons of continuous variables with normally distributed values we used 
the independent sample t-test. For non-normally distributed values comparisons were 
performed based on rank, i.e. the non-parametric Mann-Whitney U test. Comparisons 
of categorical variables were performed with the Chi-squared test (or Fisher’s exact 
test as required). Depending on the data distribution, correlation analyses were 
performed either with Pearson correlation test (normally distributed data) or 
Spearman’s rank correlation test (non-normally distributed).  
3.5.2 Linkage	  analysis	  
For each typed SNP we calculated the Logarithm of Odds (LOD) for linkage to the 
unknown disease causing mutation taking into account the phenotype (here presence 
or absence of the diarrhoea) and the pre-test probability for linkage (around 2%). A 
LOD score >3 corresponds to a post-test probability of linkage >95%. Since a large 
number of markers were tested, we carried out this procedure (multi-point linkage 
analysis) using the Allegro version 2 software package (Decode Genetics, Reykjavik, 
Iceland) that also offer analytical solutions for common pitfalls, such as incomplete 
penetrance and phenocopies.152  
3.5.3 Gene	  expression	  data	  analyses	  
Gene expression data generated by microarrays consist of a large number of variables 
representing differing overall gene expression levels. In paper II we compared gene 
expression in FGDS using a modified version of the t-test statistics, Significance 
analysis of Microarrays (SAM), which penalize small variance by adding a constant 
factor in the denominator.153 Each gene is given a score (a proxy for the t-score), with 
significance determined according to how much the actual score deviates from what 
is expected given the 0-hypothesis (that the group assignment of participants does not 





When comparing two distributions we need to take into account that gene expression 
data generally do not show normal distribution. We established the 0-distribution, i.e. 
the distribution of all possible gene scores given the actual data, by shuffling 
(permuting) the group labels 1000 times. We used this principle, called permutation 
analysis to assess significance also in the GSEA analyses as illustrated in Figure 8, 
panel C.  
Key findings were validated ranking differentially expressed genes according to the 
“rank product” procedure.154 We used the bioinformatics software package J-
Express2012 for these analyses.130, 155  
3.5.4 Enrichment	  analyses	  
The idea of enrichment analysis is to test whether groups of genes that may share 
some functionally defined role (e.g. as members of a particular pathway) are 
overrepresented (enriched) in experimental data. Enrichment analyses require the 
input of experimental data as a list of genes (e.g. from GWAS or expression analyses) 
upon which to query at least one pre-defined set of biologically related genes. There 
are several different statistical approaches out of which we used two; modular 
enrichment analysis and gene set enrichment analysis. 
Modular enrichment analysis 
Modular enrichment analysis allows experimental data to be analysed against pre-
defined gene sets from various databases. We analysed gene expression data with this 
option in the Database for Annotation, Visualization and Integrated Discovery 
(https://david-d.ncifcrf.gov/home).156 This freely available bioinformatics tool offers 
an online interface for analyses and a clustering algorithm that organizes gene sets 
originating from different biological databases into functionally related modules.157 A 
modified Fishers Test statistic (EASE score) is used to find gene sets that are 
overrepresented in the datasets. The enrichment score for a module (“functional 
cluster”) is then calculated according to P-values for gene sets within the cluster. For 





discoveries. A drawback with this method is that the input in the analyses is not 
ranked according to effect and is limited to an arbitrary significance threshold.156  
Gene set enrichment analysis 
Gene set enrichment analysis (GSEA) is an alternative approach, which employs 
ranking and avoids the threshold-restraint.158 The gene expression data were ranked 
according to differences between FGDS and healthy controls, using signal-to-noise 
ratio.159 Gene sets used in the analysis were retrieved from the GeneOntology 
database. (http://www.geneontology.org/GO.downloads.ontology.shtml).We used J-
Express2012 software (Jexpress.bioinfo.no) to perform the analysis.130, 155 The 
enrichment score (ES) obtained for each gene set is explained in Figure 8.  
Gene set enrichment analysis in IBD GWAS data  
In paper II we tested a gene set representing the GC-C pathway for enrichment in 
three publicly available GWAS datasets. The principle is illustrated in Figure 8, 
using our analysis of the IBD dataset as an example. Here, the order of genes on the 
ranked list was determined by scoring each gene according to GWAS P-values for its 
respective SNPs. The gene scores were corrected for the overall number of SNPs in 
the gene and their LD using a Brown score (Fisher based correction).160, 161, 162 
The datasets were downloaded and analysed on the online GSEA-software tool 













Figure 8. GSEA in GWAS data (inspired by Ersland KM et al. 2012 162) 
Panel A: A pre-ranked gene list was created using summary statistics from 
GWAS in IBD. Genes were scored and ranked according to P-values for 
their respective SNPs. 
Panel B:  The GC-C gene set was downloaded and queried against the 
pre-ranked list. A running enrichment score (ES) is computed, starting at 
the top and moving down the pre-ranked gene list. The ES increase 
according to the respective gene score every time a member of the 
candidate gene set coincides with a pre-ranked gene (shown as vertical 
bars “hits”), otherwise it decrease as shown by the enrichment profile 
(green). The peak of this profile marks the maximum ES, in this case 0.74. 
Panel C: The permutation/0- distribution (purple line) of maximium 
enrichment scores was obtained running GSEA 1000 times shuffling the 
genes of the pre-ranked list. The P-value for the experiment is calculated 
as the area under the curve (red hatched) at and above its maxium ES 
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3.5.5 Microbiota	  analyses	  
We decided that genetic relatedness/distance between taxa should be accounted for 
when testing statistically whether the composition of bacteria in one group differed 
statistically from the composition in another. This was done by calculating the 
number of branches in the “tree of life” (UNIFRAC distance) that separated taxa only 
present in sample A from taxa only present in sample B etc.163 The UNIFRAC 
distances were then used for visualisation of data, as shown in Figure 6, and for 
comparing statistically the microbiota composition (beta-diversity) between the 
groups. The structure of the data precludes the use of parametric tests, and we thus 
employed permutation based analysis of variance (PERMANOVA).164 Permutation 
used in statistical significance testing is explained above (see 3.5.3). 
For analysis of alpha-diversity (within sample diversity) we used the Shannon index, 
which accounts for richness (total number of different taxa) as well as the evenness of 
taxa. 165 We verified the results using other alpha-diversity measures.  
In the statistical analyses regarding specific taxa associated with FGDS, we used non-
parametric tests (Mann-Whitney) and corrected for multiple testing using the False 
Discovery Ratio (explained in section 3.5.6).103   
IBD status in FGDS was an important co-variable that we accounted for in the 
subsequent analyses. For evaluation of the impact of co-variables we used two freely 
accessible bioinformatics tools, LEfSe and MaAsLin 
(http://huttenhower.sph.harvard.edu/galaxy/) that have been developed specifically 
for analyses of the microbiota. The former employs a combination of non-parametric 
tests and the Linear Discriminant Analysis principle to identify the features in the 
data that best explain differences between groups with consistency (in this case 
regardless of IBD status) and assign an estimated effect size.166 We used the graphic 
options offered by LEfSe to illustrate our findings in paper III.  
Next IBD status and other factors associated with the microbiota (age, number of 





the groups using MaAsLin, which is a version of linear regression.167 The taxa that 
remained significant throughout this sequence of tests were ultimately validated 
comparing FGDS without IBD to healthy controls using Mann Whitney test.  
3.5.6 Statistical	  significance	  and	  multiple	  testing	  
This thesis reports the results of many statistic tests, with a high risk of false positive 
observations (type I errors). In a single experiment reported in paper II, more than 
25,000 variables were compared between two classes represented by a total of 27 
samples. As many as 1250 (5%) observations might here be expected to pass the 
nominal significance threshold at alpha=0.05 by coincidence. One common way to 
adjust significance thresholds according to number of observations is the Bonferroni 
correction, using the formula alpha = 0.05/number of tests. However, the Bonferroni 
method has been criticised for being too conservative and may increase the number of 
false negative findings (type II errors).  
One popular approach to this problem, which we adopted, is to rank all observations 
(discoveries) according to their nominal P-values, and for each estimate the false 
discovery ratio (FDR /Q). The FDR is computed as the proportion between the 
number of actual discoveries for a given nominal P-value threshold and the number 
of the expected discoveries given the 0-hypothesis.168 In the present thesis, P<0.05 is 
considered statistically significant unless otherwise indicated by the FDR correction. 
3.5.7 	  Power	  estimates	  
Given the scarcity of FGDS patients, considerations about the expected magnitudes 
of effects to study and the number of samples needed to detect these effects were an 
important part of planning the current projects. Power estimates help to predict the 
level of confidence that can be obtained to avoid pointless analyses. However, when 
studying a novel and rare disorder, available knowledge on expected effects as well 
as individuals eligible for the study are necessarily limited.  
When we decided to carry out linkage analysis, eleven family members had been 





genotyping only the affected might suffice to identify significant disease linkage with 
maximum LOD score >3. 
 
For the gene expression study (paper II) and the microbiota study (paper III) we 
estimated a minimal sample size of 10 participants per group. We presumed that 
biological effects of the GUCY2C mutation are evident in a relatively small dataset, 
possibly intermediary between what can be observed in genetically modified animals 
(where sample size of <6 may suffice) and in complex human disorders where larger 
numbers are needed.169 
 
Genetic risk variants generally show low effect size (odds ratio typically 1.5 and 
below), making it unlikely that statistically significant difference could be 
detected.170, 171 On the other hand the impact of common genetic variants could be 
stronger when present in individuals already at high risk, as for the FGDS patients. 
We therefore reasoned that a targeted and descriptive assessment of IBD-risk variants 
in FGDS patients appeared biologically well funded, meriting the exploratory study 
performed.37    
 
In our assessment of dietary habits in FGDS and healthy relatives, we calculated 80 
% power to detect 10-15 % difference in intake of a single macronutrient recorded 
with food frequency questionnaires if provided by all eligible family members. With 
the many nutrients under assessment, this study was clearly not powered to detect 
subtle differences in food preferences after corrections for multiple comparisons. 
Obtaining the dietary data was still prioritised since it could help to detect overt group 
differences for this important confounder. 
3.6 	  Ethical	  considerations	  
The Regional Committee for Medical and Health Research Ethics of Western 





Research Ethics in South-Eastern Norway (reference number 2012/286b) approved 
the studies conducted throughout this project.  
During genetic testing, we could incidentally discover genetic changes predicting 
future unpreventable and untreatable ailments and unrelated to the disorder of 
interest. Genetic analyses were however targeted either for common variants with 
presumably little impact, or towards small regions of the genome, and taken together 
this minimized the potential risk for incidental findings.  
Pedigrees displayed in paper I and II constitute a step away from an ideal of full 
participant anonymity but were considered crucial for illustrating the nature of our 
study and its findings. The participants had been informed in advance and approved 
the use of pedigrees in the scientific publications.  
 All participants or their parents were thoroughly informed about the investigations 






4.  Summary of findings 
4.1 Paper	  I	  
4.1.1 	  Patient	  demographic	  and	  clinical	  characteristics	  	  	  
From the pedigree shown in Figure 4, we studied a total of 32 family members. The 
clinical characteristics of the patients define the diagnostic features of FGDS. The 
patients typically had onset of diarrhoea in early infancy, and eight family members 
had been hospitalized within one month from birth due to dehydration and metabolic 
acidosis.  
 
Increased intestinal gas was reported in most of the patients, and several patients also 
reported recurrent abdominal pain. These symptoms resemble IBS, and in fact four 
family members had previously received this diagnosis. While these individuals did 
not fulfil IBS criteria as assessed by the current symptom questionnaire, five other 
cases did fulfil these criteria.  
 
Ten family members underwent surgery because of suspected bowel obstruction and 
in eight of them this was confirmed. The aetiologies of intestinal obstructions as 
evaluated by the surgeon were classified as either or a combination of:  coecal 
volvulus, internal hernation, ileal inflammation, and adhesional bands.  All the 
confirmed cases of bowel obstruction involved the distal small bowel and/or the 
proximal large bowel. Intensive care due to multi-organ failure was needed in three 
patients following bowel obstruction. One relative had bowel problems and died in 
infancy. Another relative with chronic diarrhoea died at age 50 following surgery for 
bowel obstruction.  There is no other information indicating premature death.  
   
Seven patients had been treated for suspected IBD, in all cases affecting the terminal 





We found reports on dilatation of the small bowel in absence of obstruction in several 
patients and long segments of gross dilatation in three patients, consistent with 
intestinal dysmotility.  
Deficiency of vitamin B12, esophagitis and urolithiasis had been reported in six, five 
and four patients respectively.  
4.1.2 	  Genetic	  characteristics	  of	  FDGS	  
We found linkage to FGDS on the short arm of chromosome 12 with a LOD-score of 
5.1. This region comprised 28 putative protein-coding genes, including GUCY2C, 
known for its role in bacterial toxin induced diarrhoea. By DNA sequencing, we 
discovered a novel missense variant, c.2519G→T in exon 22 of GUCY2C, 
representing an amino acid substitution from serine to isoleucine in position 840 in 
the catalytic domain of GC-C. We found that baseline activity was unaffected by the 
mutation, but the variant GC-C responded with higher activity than the wild-type GC-
C upon ligand stimulation. We also found that the amount of uroguanylin needed to 
stimulate the mutant receptor is lower than in the normal receptor. This suggests that 
the concentrations of uroguanylin present in the intestine could result in abnormally 
elevated levels of cellular cGMP in intestinal cells harboring the mutant receptor 
(gain-of-function). 
4.2 	  Paper	  II	  
4.2.1 	  Assessments	  of	  IBD	  risk	  loci	  in	  FDGS	  patients	  	  
We found that the candidate set of genes representing members of the GC-C - CFTR 
pathway displayed significant enrichment of association in IBD case-control genetic 
data but not in CD or UC separately.  
 
The ratio of particular risk allele carriage between FGDS patients with and without 
CD showed minimal deviation from 1.0 (i.e. no difference between the two groups) 






Figure 9. The risk allele ratio in FGDS with (n=8) versus without IBD 
(n=14). Each spot represents one of 163 IBD risk alleles. RS5743289 in 
NOD2 is a substantial outlier with 12.3 fold higher frequency in FGDS 
patients with IBD than in those without IBD. 
 
4.2.2 	  Global	  gene	  expression	  changes	  in	  the	  distal	  small	  bowel	  mucosa	  of	  
FGDS	  patients	  
We investigated global gene expression in biopsies from the terminal small bowel in 
FGDS patients, unrelated CD patients without ileal inflammation and unrelated 
healthy controls.  
 
Twenty-one genes were significantly differentially expressed when comparing FGDS 
to healthy controls.  Six genes encoding metallothioneins were down regulated in 
FGDS patients, and four of these were verified using qPCR. Qualitative assessment 
of biopsies using immunohistochemistry suggested that transcriptional down 
regulation of metallothioneins in FGDS was translated also to the protein level. 
Metallothionein related terms prevailed in pathway analyses of the gene expression 
data. We considered tissue zinc depletion as a possible explanation for these findings, 
but no differences were observed in plasma zinc between FGDS and healthy controls. 
Metallothionein down regulation in intestinal biopsies from unrelated cases with IBD 






























































4.3 	  Paper	  III	  
4.3.1 	  Stool	  calprotectin	  and	  bacterial	  characteristics	  of	  FGDS	  patients	  
Of the 20 FGDS patients in this study, five had concomitant CD. In this group, 
disease activity as assessed clinically was comparable to unrelated CD, while stool 
calprotectin was significantly lower. 
We found that the faecal bacterial composition differed in FGDS patients as 
compared with unrelated as well as related healthy controls and unrelated patients 
with IBD. The gut microbiota of healthy relatives of FGDS patients was similar to 
that of unrelated healthy controls. Alpha diversity in FGDS patients was similar to 
healthy controls, whilst significantly reduced in IBD as compared with FGDS 
patients and healthy controls. 
We found that 28 microbial taxa were changed in FGDS patients compared to healthy 
controls when stratifying for concomitant CD and controlling against healthy 
relatives. The quantitatively largest differences were seen within the phylum 
Firmicutes, including a marked depletion of the genus Faecalibacterium. Loss of 
Bifidobacterium in the FGDS patients was near to total. On the other hand, 
Enterobacteriaceae and methane producing archaea were increased in FGDS. 
Intake of fat, protein, carbohydrates, fibre, added sugars and alcohol as reported in 
food frequency questionnaires was similar in FGDS patients and healthy relatives.  
4.3.2 	  Microbiota	  associations	  with	  IBD	  in	  FGDS	  
We found that Faecalibacterium was significantly lower in FGDS patients affected 
by CD than in those unaffected by CD, but still lower in FGDS patients without CD 
as compared with healthy relatives. There was a tendency towards loss of alpha-
diversity in CD affected versus non-CD affected FGDS patients, but the difference 
was not statistically significant. We found that diarrhoea was associated with CD 






5.  DISCUSSION  
5.1 	  FGDS	  -­‐	  a	  novel	  inheritable	  disorder	  
The experiments performed in paper I leave little doubt that the c.2519G→T variant 
in GUCY2C is the cause of familial diarrhoea in the Norwegian family we studied. 
Deletion of Gucy2c by genetic engineering had previously been performed in mice as 
part of general studies of the functions of this gene, but our work was the first to 
report of a human disorder caused by a mutation in GUCY2C.2 The inheritance 
pattern and genetic findings strongly suggested this was a novel monogenic disease, 
and the medical literature provided no similar entity with the overall constellation of 
symptoms and complications that we observed in our patients. We named the 
disorder familial GUCY2C diarrhoea syndrome - FGDS.  In the following, I will 
discuss opportunities, interpretations and limitations pertaining to our work along 
four principal directions: 
1) How to diagnose FGDS in other patients? 
2) What can FGDS teach about the function of GUCY2C? 
3) Can FGDS provide insights of general relevance and relevant 
to other diseases? 
4) How should we manage FGDS patients in the clinic? 
Lastly, I will provide some suggestions for further research building from our studies. 
5.2 	  Defining	  and	  diagnosing	  FGDS	  	  
Throughout the papers presented in this thesis, the diagnosis of FGDS was based on 
carriage of the c.2519G→T mutation in GUCY2C. While mutation carrier status is a 
logical diagnostic test that correlated closely with the presence of diarrhoea, some 
criteria could help the clinician to decide when to suspect and how to proceed in 
diagnosing FGDS in a patient. Before defining these criteria I will outline the main 







Reported stool frequency ranged from 0.5 to 20/day, showing that diarrhoea is not a 
constant trait in mutation carriers. The reported age of onset of diarrhoea varied, and 
holds intrinsic recall bias as to the memory of the participant or a parent. The overall 
ratio of hospitalisation for dehydration within one month of birth was approximately 
30%, but more than 50% among the younger participants, supporting that diarrhoea 
presents in very early age. In those hospitalized in neonatal age for dehydration, 
improvement occurred in most within a couple of days to weeks, an observation that 
differs from other congenital diarrheal disorders where neonatal dehydration may 
herald severe continuous diarrhoea.30  
 
Meteorism 
Almost all FGDS patients reported abnormal amount of intestinal gas, a rather 
subjective symptom, but this symptom was often felt socially disturbing due to noise 
or associated soiling of underwear and the symptom seems required for a diagnostic 
algorithm of FGDS. The meteorism could be explained by intestinal dysmotility.174, 
175 
 
Inflammatory Bowel Disease 
Depending on how strict criteria we used, 20-25 % of adult FGDS patients have 
developed IBD. While the absolute numbers are small, our data indicate that young 
people with FGDS are at increased risk for developing IBD, categorized as or 
resembling CD, and diagnostic criteria for FGDS must account for this complication. 
Delineating potential pathophysiological aspects of the IBD manifestation was a 
major emphasis of this thesis. 
 
Small bowel obstruction 
Among adult FGDS patients, one in three have experienced small bowel obstruction 
needing surgery at least once in life and diagnostic criteria for FGDS must include the 
possibility of this complication. Apart from a strong tendency to involve the distal 





during surgery support that a tendency towards intestinal torsion results from 
impaired intestinal motility. Potential mechanisms for dysmotility and bowel 
obstruction are discussed in chapter 5.3. 
 
Heritability 
In our study chronic diarrhoea was inherited in an autosomal dominant pattern with 
penetrance at >30% by one month of age and 100% by adolescence. The c.2519G→T 
variant in GUCY2C may arise de novo, and absence of relatives with chronic 
diarrhoea does not rule out FGDS. Other variants in GUCY2C might also give rise to 
diarrhoea with a similar mechanism but a different pattern of inheritance. When three 
brothers in the current family were evaluated 20 years ago, the geneticist noted that 
their history resembled CSD,176 but differed from this disorder that was thought to be 
autosomal recessive, by showing autosomal dominant heritability and a milder 
phenotype.177 
 
A couple of years after our first paper was published, Janecke and coworkers showed 
that de novo heterozygote gain-of-function variants in GUCY2C or homozygote / 
compound heterozygote loss-of-function variants in the SLC9A3 gene (encoding 
NHE3 immediately downstream of GUCY2C) cause CSD.178, 179 These patients 
generally showed more severe diarrhoea than FGDS, and earlier development of IBD 
and intestinal obstructions.179 The severity of presentations correlated with the 
functional effects of different activating mutations in GUCY2C. These findings 
suggest that CSD and FGDS could be regarded as variants of the same disorder.  
 
Terminology 
In this work we have agreed to maintain FGDS as a distinct disorder, but 
acknowledge that the terminology might be reconsidered. The name Familial 
GUCY2C diarrhoea syndrome would not include disorders caused by variants in 
SLC9A3. Dysmotility was reported in FGDS as well as CSD caused by GUCY2C 
variants but not in CSD patients with SLC9A3 variants. However, intestinal 





for distinguishing one entity from another could be questioned. If we in the clinic opt 
to classify FGDS as variant(s) of CSD, it could be useful to subdivide the entity 
according to age of onset: neonatal, infant, juvenile. The CSD entity should still be 
maintained distinct from other diarrheal disorders with sodium loss, such as the type 
associated with congenital malformations and variants in SPINT2, as well a 
Microvillus Inclusion Disease, caused by variants in MYO5B.179, 180  
 
Genetic testing  
It seems relevant that genetic testing for suspected FGDS should include scanning of 
the SLC9A3 gene. In fact, I would propose that for all conditions with a presentation 
form similar to FGDS and CSD, genetic testing for GUCY2C, SLC9A3, CFTR, 
SLC26A3, SPINT2 and MYO5B should be performed as a gene panel assessment. 
 
Proposed diagnostic criteria for FGDS: 
Major criteria:  
1. Chronic loose stools with frequency ≥ 3 times a day lasting more than 3 
months, onset in childhood  
2. Neonatal onset diarrhoea with dehydration (loss of >10% of birth weight) 
3. Increased loss of sodium in the stools. 
 
Minor criteria:  
1. At least one first-degree relative affected by chronic diarrhoea 
2. Intestinal gas at levels perceived to be socially disturbing 
3. Neonatal dehydration with hyponatraemia  
4. Spontaneous improvement of neonatal diarrhoea 
5. Dehydration needing hospitalization during intercurrent gastrointestinal 
infections 
6. IBD following a long period (>1 year) of chronic diarrhoea 
7. Small bowel obstruction with signs of chronic intestinal dysmotility 
8. Ileocoecal volvulus 





These criteria represent characteristics of use to suspect FGDS but with a large 
number of different inheritable diarrheal disorders, a final diagnosis should only be 
made in support of genetic variation compatible with gain-of-function in GUCY2C.30 
For patients that I meet in the clinic I have used the rule of thumb that at least one of 
the major criteria, and three of the minor criteria should be fulfilled prior to initiating 
genetic testing for FGDS. This rule has however not been formally evaluated as to its 
sensitivity and specificity. As in any clinical decision, sound judgement should be 
exercised. Irritable bowel syndrome (IBS) is a common disorder that run in families 
and may resemble FGDS, but unlike the latter, IBS tend to present later.181 In patients 
with relatively late-onset diarrhoea, I would recommend that at least four minor 
criteria are needed to support suspicion of FGDS and the initiation of genetic testing.  
5.3 	  What	  do	  our	  studies	  tell	  about	  GUCY2C	  function?	  
The involvement of GC-C (as encoded by GUCY2C) in diarrhoea was discovered  
almost 40 years ago, following the efforts to identify the receptor for ETEC toxins.182 
Apart from the toxins, GC-C is also activated by small peptides, guanylin and 
uroguanylin secreted from the intestinal wall.183, 184 As the GC-C receptor itself, these 
peptides are mainly located along the small and large bowel lining.185, 186 Regulation 
and effects of GC-C activation have been outlined in subsequent studies using cell-
models and genetically engineered mice.148, 187, 188, 189, 190 Secretion of the guanylins is 
regulated by nutrients, and GC-C seems to be part of a sensing-effector circuit 
involved in feeding.191  
The genetic models provide extensive opportunities to carry out experimental 
interventions and strictly control for effects of confounding environmental factors 
such as microbes and nutrients. The model-organism principle was exploited in paper 
I where experiments in a cell-line revealed that the c.2519G→T mutation in 
GUCY2C results in increased activation of GC-C and that the increased activation 





Unlike the animal and cell-based model systems, monogenic disorders such as FGDS 
offer the opportunity to record symptoms and complications that occur over the life 
span of a complex human organism, and may provide new and unexpected insights in 
the biology of single genes (a human model system).3, 192 As such, the present study 
of FGDS allowed us to gain insights in the long-term effects of GC-C activation in 
humans, and also to perform proof-of-concept interventions. Although patient size is 
limited, such proof-of-concept interventions may further inform the pathophysiology 
and open for treatment of even more common disorders with similar symptoms. In 
our case, an observational intervention with metformin had been tried on the basis of 
its potential to activate AMPK and thereby impair chloride efflux through CFTR 
(Figure 7) with some possible beneficial effects.  
Our observations suggesting dysmotility, i.e. perturbations of gut peristaltic 
movements in FGDS, motivated the extensive work on this topic performed by dr. 
Von Volkmann.174, 175 Patients with FGDS display increased non-occlusive small 
bowel contractions and delayed colonic transit.174, 175 Intestinal motility is regulated 
through a complex and still insufficiently understood crosstalk involving mechano- 
and chemo-sensors in the gut, the entero-endocrine as well as the autonomic and the 
enteric nervous system. 193 Supporting that the GC-C pathway interacts with the 
enteric nervous system, FGDS patients display different circulating levels of the 
neurotransmitter serotonin than healthy following a meal.175 However the GC-C 
activating ligands stored in various cell types throughout the gut show little degree of 
co-localization with serotonin-secreting cells.194 
Intestinal dysmotility has to our knowledge not previously been linked with 
GUCY2C, and this finding emphasizes the multiple functional impacts of this gene.    
Considering GC-C as a member of the guanylate cyclase family, the finding may not 
be surprising. Guanylate cyclase-A, is one membrane-bound member of this family, 
expressed in the heart and blood vessels and a key regulator of vascular smooth 





Cyclic GMP generated by soluble guanylate cyclase (another member of the family) 
decreases smooth muscle tone in blood vessels as well as the gut by facilitating 
calcium transport.196 197 There is evidence of a cross talk between membrane bound 
GC and soluble GC, which could provide an explanation for the effect of GC-C 
activation on intestinal motility.198 Also cGMP generated in the epithelium by GC-C 
may be transported across cell-boundaries and thereby regulate intestinal smooth 
muscle contractility more directly.197  
Dysmotility probably explains delayed intestinal transit, gas and susceptibility to 
twisting of the gut in FGDS. This is the extreme of a continuum, and effects from 
GUCY2C under normal physiological conditions likely serve beneficial purposes. 
GC-C signalling appears to be coordinated according to feeding patterns, and could 
help nutrient uptake by tuning peristaltic movements according to the need for 
propulsion yet assuring optimal absorbtion.191, 199, 200 This is in line with the notion 
that GC-C activation promotes food absorbance also by moderating the mucus 
barrier.191  
In the biopsies from the distal ileum of FGDS patients in paper II, only a modest 
number of genes were differentially expressed compared to healthy controls. Down-
regulation of metallothionein-genes was a striking observation in these data. The 
metallothioneins are low molecular proteins with strong antioxidant and metal-
binding properties due to a high content of cysteine residues. While protecting the 
organism from metal toxicity and oxidative stress, metallothioneins are also crucial 
for storage and shuttling of physiologic metals, most importantly zinc.201 The 
availability of zinc is a key regulator of tissue metallothionein expression, and we 
asked whether the gene-expression findings might mirror zinc depletion e.g. due to 
diarrhoea.201 Zinc depletion could amplify GC-C activation and thus aggravate 
diarrhoea in FGDS, but while shortage of tissue samples forbade the optimal 
assessment of this matter, such an explanation was neither supported by plasma zinc 






Tissue architecture may impact on global gene expression recordings in whole-tissue 
samples due to cell-type specific transcriptional activity.19 For example GC-C 
activation could promote cell-differentiation and decrease epithelial proliferation, 
whereas intestinal inflammation may increase epithelial proliferation.4, 203 In our 
study, deviations from normal architecture (fibrosis/granulation tissue/inflammation) 
were only seen in three samples (FGDS patients with CD). When testing for bias by 
performing an analysis without these samples, findings remained stable.  
We believe that regulation of metallothionein expression by physiological levels of 
GC-C activity may serve a signal transducer function influencing epithelial zinc and 
redox status,204 and thereby host-microbiota interactions.205, 206  
The differences in overall microbiota composition in FGDS compared to controls we 
found in paper III did suggest a role of GUCY2C in shaping the intestinal microbiota. 
While GUCY2C has not figured among the genetic factors associated with the 
intestinal microbiota in population-based studies, clearly these studies hold major 
limitations as shown by little overlap in gene-microbiota associations between the 
different studies.107, 207, 208 On the other hand, population studies have shown stool 
consistency to be one of the strongest determinants of the intestinal microbiota, 
supporting that even small transepithelial fluid shifts induced by GC-C may influence 
intestinal ecology.209, 210 GC-C induced ion transport across the gut epithelium may 
also impact on the intestinal microbiota by changing the pH.211 We have indeed 
verified that the intestinal lumen is more alkaline in FGDS compared to healthy 
controls, suggesting another factor linking GC-C activation and the intestinal 
microbiota.175, 211  
Taken together our findings align with mounting evidence in human as well as animal 
studies indicating that GC-C signalling may serve important host benefits, including 
the defence against pathogens by regulation of the intestinal microbiota.212, 213  
The involvement of GC-C in intestinal immune function has been suggested by 
studies in Gucy2c knock-out mice, which show increased susceptibility to invasive 





signalling may be especially important in the neonatal period.186 In contrast to FGDS, 
children with GC-C inactivating mutations experienced neonatal severe constipation 
(meconium ileus) mimicking CF and retained liability to severe infections throughout 
infancy.215, 216 Some of this liability can been attributed to perturbations of epithelial 
differentiation and barrier function (including the mucus layer) in the absence of 
appropriate GC-C signalling.212, 213, 217 Our studies of FGDS has added a new piece to 
this picture, by showing that also increased GC-C signalling may adversely affect 
immune function and contribute to the development of intestinal inflammation in 
humans.  
5.4 Can	  FGDS	  provide	  insight	  of	  general	  relevance	  and	  relevant	  
to	  other	  diseases?	  
Although afflicted by a rare disorder, FGDS patients display clinical similarities with 
the common condition IBS with diarrhoea (IBS-D), and are liable to develop other 
common clinical conditions such as IBD and small bowel obstruction. Monogenic 
disorders may overlap with common disorders regarding single genes and pathways 
involved,3, 218 and the demarcation between monogenic and complex diseases is most 
appropriately considered a continuum (Figure 2).  Along this concept, studies of 
monogenic disorders may help to elucidate mechanisms of relevance also to complex 
disorders involving similar pathophysiological components or similar symptoms. 
Such studies thus hold general relevant, and may ultimately pave the way for 
therapies of relevance far beyond the monogenic condition in which they are 
performed.3 My main emphasis has been the identification of factors relevant to 
understand why some FGDS patients develop IBD, and whether these factors are 
shared with IBD patients without FGDS.  
Inflammatory Bowel Disease 
In the gene set enrichment analysis (reported in paper II) we found that genes 
belonging to the GC-C signalling pathway were overrepresented among the GWAS 
findings in IBD. Rather than considering association statistics of single genes, but as 





whether the GC-C gene set may overlap with pathways involved in regular IBD.99, 218 
As noted above, gene set selection may be biased and the putative involvement of 
genes in more than one pathway (which commonly is the case) may confound GSEA 
outcomes.102 Regardless of the GSEA, even individual members of the GC-C 
pathway were associated with both types of IBD at genome-wide significance levels 
(i.e. SLC9A3, SCL9A2, SLC26A3 and PRKAR2A, PRKAA1), supporting our 
observations from the GSEA that IBD in FGDS shares pathophysiological 
mechanisms with conventional IBD.  
A notable segregation of risk variants in NOD2 was found in FGDS patients with 
concomitant IBD (Figure 9). NOD2 encodes a cytosolic receptor for bacterial 
patterns and unfolded proteins. Coordination of the responses to these exposures e.g. 
engulfment and neutralization by autophagy are key functions of NOD2 relevant to 
inflammatory pathways.63 Variants in NOD2 are the strongest genetic risk factors for 
CD and are mainly associated with the ileal subtype, i.e. a phenotype similar to that 
observed in FGDS patients with IBD. 68, 219, 220, 221 Since the FGDS patients are 
closely related and therefore share a common genetic background, segregation of 
genetic variants beyond GUCY2C may occur by chance and unrelated to FGDS 
pathophysiology. However, in the genotyping of IBD risk variants, NOD2 was a 
solitary and substantial outlier. This observation is supported by the fact that the 
NOD2 variants appear to originate from five independent founders. Further 
supporting a disease modifying role of NOD2 in FGDS, and even suggesting an allele 
dosage effect, the only two FGDS patients homozygous for NOD2 risk variants 
displayed a particularly severe IBD phenotype requiring extensive surgical 
interventions. All but one FGDS patient carrying NOD2 risk variants had been 
diagnosed and treated for IBD before genotyping, minimizing the risk of 
ascertainment bias.  
Metallothionein down-regulation has previously been reported in studies of the 
intestinal mucosa of patients with IBD, and its occurrence in FGDS raises the 
question whether it may represent a common factor of the inflammatory 





controls with CD was limited, and we were only able to determine a non-significant 
trend towards metallothionein down-regulation in our conventional CD samples. 
Epithelial metallothionein expression may be affected by the intestinal microbiota, 
but may also serve as a signal transducer important for the epithelial clearance of 
bacteria.224, 225, 226, 227 The underlying biology of metallothionein involvement in gut 
inflammation may indeed relate to its role as a mediator between NOD2 bacterial 
sensing and subsequent bacterial removal by autophagy.227 Impaired autophagy 
favours an inflammatory response to bacteria, and is an established risk factor for 
development of CD.62, 64 Metallothionein down regulation and NOD2 risk variants 
may thus in sum constitute additive liability factors for CD, linked to GC-C activation 
in FGDS, potentially providing an explanation for the clinical affections. 
In paper III we reported that FGDS patients display changes in the gut microbiota that 
could pose a relevant contribution to development of IBD. Most strikingly, FGDS 
patients displayed remarkable loss of the bacterial species F. prausnitzii and 
increased abundance of Enterobacteriaceae. These changes are often seen in CD, but 
while both can be speculated to contribute to inflammation, they may also both be 
secondary markers of inflammation and gut barrier alterations.64, 92, 93, 228, 229 This 
“chicken and the egg problem” is inherent to the interpretation of all cross-sectional 
data on the intestinal microbiota. In our study, stratification of FGDS patients 
according to IBD status combined with stool inflammatory markers helped to control 
for the potential confounding effect of inflammation, however similarities between 
FGDS and IBD could partially be explained by the fact that both groups are affected 
by diarrhoea, which is associated with total loss of bacteria and increased oxygen 
tension, again favouring an ecology enriched for Enterobacteriaceae and disfavouring 
F. prausnitzii.206, 230 
Similar to FGDS, diarrhoea in IBD may partially depend on impaired 
sodium/hydrogen exchange through NHE3.20, 231 Whether this is a primary or a 
secondary event in IBD may be hard to settle, since this ion channel display complex 
multidirectional relationship with the intestinal microbiota, microbial metabolites and 





deficient of NHE3-activity, our studies support that transepithelial fluid shifts may 
initiate and sustain inflammation. Such pro-inflammatory effects may be mediated by 
changes in the intestinal microbiota.233, 234 Finally, other human studies support that 
alterations of the intestinal microbiota may precede development of IBD in 
individuals with genetic risk.235, 236, 237 In our data, the similarities between FGDS 
patients with and without IBD, may indeed indicate that intestinal microbiota 
alterations precede the intestinal inflammation, but longitudinal studies are needed to 
confirm this possibility. 
Bowel obstruction  
The high lifetime incidence of acute bowel obstruction observed in FGDS and CSD 
has to our knowledge not been reported in other diarrheal disorders, suggesting that it 
is a complication specifically linked to GC-C signalling. We were particularly 
intrigued by the constant location (ileocoecal junction), but apparently variable 
aetiology of small bowel obstruction (adhesional bands, inflammation, volvulus). 
Torsion of the intestine at the junction between small and large bowel has been seen 
during surgery in several FGDS patients and characterised as coecal volvulus in three 
patients. This kind of intestinal obstruction may resolve if the bowel untwists in a 
timely manner.238, 239, 240 Recurrent intestinal torsion could explain spontaneously 
resolving episodes of strong abdominal pain needing hospitalisation in some FGDS 
patients. Apart from a freely movable ileocoecum observed during surgery, the 
tendency to develop volvulus in FGDS is likely explained by GC-C related gut 
dysmotility, which may predispose for twisting and impair untwisting of the gut.178, 
241   
Intestinal torsion may eventually lead to compromised blood flow and intestinal 
ischemia and potentially to a so-called ischemia/reperfusion (I/R) injury.242 
Reperfusion of hypoxic tissues following surgical treatment releases reactive oxygen 
species and inflammatory mediators creating inflammation and scars locally, and 





Twisting of the coecum would not necessarily require surgery if spontaneous 
untwisting takes place, but an I/R injury could still be sustained, resulting in epithelial 
apoptosis, bacterial translocation across the bowel wall, inflammation and/or fibrotic 
adhesions. It could be speculated that such events induce different types of pathology 
observed in FGDS, including intestinal inflammation, as illustrated in Figure 10. 
 
Figure 10. Concept of ischemia / reperfusion injury due to intestinal torsion 
as an event leading to variable pathology observed in the ileocecal region 
in FGDS. Photo used with permission from the patient.   
That hypoxia could have general relevance in the pathogenesis of IBD has been 
suggested e.g. by an association between high-altitude travelling and disease flares, as 
well as over-expression of hypoxia inducible pathways in animal IBD models.246, 247 
Interestingly the liability to develop injury after I/R may be modulated by the 
intestinal microbiota through NOD2 signalling and autophagy.248 We noted that 
among FGDS patients with intestinal obstruction, NOD2 variants demarcated those 
that also developed inflammation. We are unable to determine whether 
metallothionein down regulation impacts on autophagy in FGDS, but we note that 
metallothionein up regulation has been associated with better outcomes after I/R 
injury.249 Moreover animal models have suggested a role of guanylate cyclase 





fluid status as well as cellular energy utilization, which may all be critical factors in 
the I/R injury.7, 245 The fluid losses that follow ion-channel dysfunction in ischemia 
could be further aggravated by GC-C deregulation in patients with FGDS.  
Irritable bowel syndrome 
IBS affects almost 10% of the general population and is usually categorized 
according to the predominant stool quality, diarrhoea (IBS-D) or constipation (IBS-
C). FGDS shows striking similarities with IBS-D regarding abdominal pain, stool 
consistency, meteorism, and influence of diet upon symptoms.150, 251 On the other 
hand, pharmacological GC-C activation is employed to treat IBS-C, showing that IBS 
like symptoms can arise at both extremes of GC-C activation.6 Supporting that GC-C 
signalling contribute mechanistically to IBS, its ligands were found up regulated in a 
study of mucosal gene expression in IBS-D.252  
Intestinal dysmotility is thought to be one important factor in IBS, but its exact role 
and underlying mechanisms are not known.251 That loose stools correlate with fast 
intestinal transit has been a prevailing belief.210 Extensive studies of intestinal 
motility in FGDS show that this clearly cannot be regarded as a universal 
principle.174, 175 While affected by diarrhoea, FGDS patients have prominent delay of 
colonic transit. Also as reported in IBS-C, and unlike healthy controls, FGDS patients 
displayed no rise in postprandial blood serotonin level.175, 253 Moreover the FGDS 
patients have some stool characteristics that are usually associated with constipation 
rather than diarrhoea, including a normal alpha-diversity and enrichment of 
Methanobacteria.210, 254  
Methanobacteria are the sole producers of methane in the gut, and the presence of this 
gas has been used as diagnostic marker for IBS-C.253, 255 There are data indicating that 
methanogenic bacteria are favoured by slow intestinal transit, but also that methane 
can slow intestinal propulsions by changing smooth muscle contractility.254, 255 We 
have not assessed whether intestinal methane production induces dysmotility in 
FGDS. However our findings suggest that changes in intestinal motility and the 





5.5 How	  should	  we	  manage	  FGDS	  patients	  in	  the	  clinic?	  
Conceding that the observations made in the family studied in this project may only 
partially be representative for patients with other GUCY2C variants and still different 
genetic and environmental background, I will present some suggestions for the 
clinical management of FGDS based on current pathophysiological insight.  
5.5.1 Causal	  treatment	  
Any treatment given to FGDS patients should be supported by a perceived benefit 
weighed against potential side effects. A novel class of GC-C inhibiting drug is under 
development, but given the generally long process of drug development pipelines, 
these will probably not be commercially available for some time.256 An available 
candidate, N-acetylcystein, has been shown to supress GC-C signalling in vivo and in 
vitro, and alleviate intestinal inflammation in an animal model. It is well tolerated 
during long-term treatment in patients with chronic airways disease.257, 258, 259, 260 As 
such, off-label prescription of N-acetylcystein in patients with FGDS may be 
considered, awaiting controlled clinical studies. 
5.5.2 Diarrhoea	  
FGDS patients are particularly vulnerable to severe diarrhoea during the neonatal 
period, during intestinal infections and following acute intestinal obstructions. Since 
weight loss may be the only sign of dehydration in the neonate,261 weight and 
symptoms of new born offspring of patients with FGDS should be monitored the first 
weeks of life in order to avoid fluid and electrolyte derangements.262  
Rotavirus infections have been associated with severe complications in FGDS, and 
given the safety profile of the current rotavirus vaccine, we recommend its use in 
infants with FGDS.263 
We have not confirmed any cases of enteritis caused by ETEC infections in FGDS, 
which theoretically could cause severe symptoms in the context of the gain-of-





order to prevent any infectious diarrhoea, FGDS patients are recommended to pay 
attention to hygiene and avoid unsafe foods, especially during international travel. 
With approval of the regional Ethical Committee, we performed an open treatment 
trial in FGDS with the drug metformin. This drug activates AMPK and inhibits PKA 
and could thus potentially diminish fluid efflux through CFTR (Figure 7). A 
significant, but modest decrease in diarrhoea was reported in the patients. The anti-
diarrheal effect of this drug was later corroborated by an independent group.264 
However, one patient developed small bowel obstruction during treatment. As this is 
a complication experienced by several relatives with FGDS not taking the drug, and 
not a known side effect of the drug, any causal link is unclear. Still, the event 
discouraged any further use of metformin in our patients.  
The intestinal dysmotility in FGDS is a known predisposing factor for diarrhoea 
secondary to small bowel bacterial overgrowth.174, 175 This phenomenon, often 
diagnosed with the support of a lactulose-hydrogen breath tests, might be considered 
when intestinal gas and fluid losses are extensive. While not a constant finding, 
several FGDS patients reported relief of diarrhoea after courses of metronidazole or 
ciprofloxacin, antibiotics typically used to suppress small bowel bacterial 
overgrowth. One particular case warrants mention: An elderly FGDS patient 
underwent ileocoecal resection due to coecal volvus, and following surgery she 
continued to pass large amounts of diarrhoea, even after the ileostomy was converted 
to an ileocolonic anastomosis. She showed renal insufficiency related to dehydration 
and was treated regularly with intravenous rehydration. Shortly after a course of 
metronidazole fluid losses subsided and renal function normalised.  
The observations related to antibiotics are of interest in connection with our own 
findings of a perturbed intestinal microbiota in FGDS. One common approach in 
altering the intestinal microbiota has been probiotics. The probiotic genus 
Bifidobacterium, which was almost absent in FGDS may relieve diarrhoea by a 
stimulating effect on ion channels.265 Whether Bifidobacterium provided in probiotic 





possibility to specifically correct disturbances in the intestinal microbiota, may also 
hold relevance for FGDS patients.266 
5.5.3 Bowel	  obstruction	  
When a patient with FGDS ceases to pass stools and experience abdominal pain, 
bowel obstruction should be suspected. While true intestinal obstructions needing 
surgery have occurred in ten FGDS patients, several have also been hospitalised due 
to pending bowel obstruction that resolved spontaneously. Aberrations of intestinal 
motility likely predispose for intestinal twisting as well as intussusception, which 
both may lead to the frank or intermittent bowel obstruction observed. Small bowel 
intussusceptions have in fact been observed transiently during routine 
ultrasonography in children and one adult with FGDS (unpublished observations), but 
these were not accompanied by pain or other symptoms of obstruction.  
Surgery pre-disposes for adhesive bands, which again may lead to bowel 
obstructions. The decision to perform explorative abdominal surgery should thus be 
carefully contemplated, probably using standard guidelines. To our knowledge all but 
one case of bowel obstruction in need of intestinal resection have been treated with a 
primary anastomosis. In the one case where ileostomy was preferred, a subsequent 
early conversion to ileocolonic anastomosis was found necessary to decrease fluid 
losses. This observation is of relevance to choice of anastomosis in FGDS patients 
undergoing intestinal surgery. Our data suggest that FGDS patients may be 
particularly susceptible to I/R injury, with local as well as systemic inflammation 
(with multi-organ failure) following bowel obstruction.  
We recommend that FGDS patients with suspected bowel obstruction should be 
admitted without delay to a hospital that can provide state-of-the art surgical and 






5.5.4 Inflammatory	  Bowel	  Disease	  
Patients with FGDS should avoid tobacco, a known risk factor for development of 
CD.  We have insufficient evidence to claim that IBD-like microbiota changes 
(dysbiosis) in FGDS play a role in their risk for development of CD. While some 
patients have reported a benefit of antibiotics against diarrhoea (see above), it would 
still be prudent to use antibiotics judicially, since these may exacerbate dysbiosis and 
enhance the risk of IBD.268, 269 Our data do not justify deviations from standard 
guidelines regarding treatment of IBD in patient with FGDS. Given the high 
proportion of FGDS that experience long-term remission from CD, the need for 





6. Conclusions and future perspectives 
6.1 Conclusions	  
The current project has outlined the clinical characteristics of a new monogenic 
disorder and its causal factor in the form of an activating genetic variant in GUCY2C, 
and thereby provided a new source of knowledge about this gene and a target for 
genetic testing in patients with similar symptoms. Our investigations of FGDS 
patients have highlighted changes in small bowel gene expression and the gut luminal 
microbiota supporting that GUCY2C contributes to the interplay between the human 
host and its resident microbiota.212, 213 The relevance of such interaction for 
development of IBD in a subset of FGDS patients is supported by segregation in this 
group of genetic risk variants in NOD2, a receptor for microbial patterns. Lastly, 
pathway based analysis supports that changes in the GUCY2C pathway may be risk 
factors for development of IBD in the general population.  
6.2 Future	  perspectives	  
6.2.1 Treatment	  
Development of treatments for GC-C induced diarrhoea might not only benefit 
individuals with the rare disorders FGDS and CSD. A drug that partially blocks GC-
C activity could also help to reduce morbidity due to infections with ETEC, and thus 
potentially save thousands of lives.1, 256 Based on its GC-C suppressing effect in 
mouse intestine and few known side effects in humans, N-acetylcystein should be 
tested in controlled clinical trials in FGDS.  
Our studies support the potential of GC-C targeting drugs in IBD as well as in IBS. 
Advancement and preclinical evaluations of such drugs may be facilitated by novel 
methods of gene editing and model organisms, such as intestinal organoids or knock-





6.2.2 Microbiota	  	  
Further studies that explore the relationship between diet, microbiota and GC-C 
signalling are awaited and more studies are needed to clarify whether the influence of 
GUCY2C on the intestinal microbiota is relevant for clinical outcomes. Future studies 
should evaluate the potential to identify subsets of GC-C related disorders (e.g. IBD 
and IBS) based on microbiota profile, and to tailor treatment accordingly.  
The lessons from FGDS and the animal models, ask for prospective studies that 
account for multiple levels of GC-C signalling. The availability of GC-C activating 
drugs provides an excellent opportunity and a strong rationale to do so.197  
6.2.3 GC-­‐C	  and	  IBD	  	  
The existing paradigm concerning IBD genetic risk has mainly considered effects 
elicited in the intestinal wall, e.g. on epithelial barrier, innate and adaptive immune 
responses towards the microbiota.21 GUCY2C and other genes involved in ion 
transport do impact on epithelial barrier, but our studies supports the concept that 
these inheritable factors can contribute to development and sustainment of IBD also 
by changing the luminal compartment and thereby the microbiota itself.235, 236, 237 
Future studies should evaluate mechanistically this hypothesis and whether applicable 
to GUCY2C or any of the other IBD risk variants. Such studies should not ignore 
effects on the mucus layer, which may be a crucial factor in the interaction between 
GC-C signalling and the microbiota.212  
Based on the disease trajectories in FGDS patients we have proposed that episodes of 
hypoxia due to twisting of the gut could be one initiating factor for development of 
IBD. This hypothesis can be further evaluated by providing careful follow-up of our 
patients and obtaining good symptom descriptions.  
6.2.4 GC-­‐C	  and	  IBS	  	  
IBS is a heterogeneous disorder in terms of stool pattern, severity, response to 





on our findings in FGDS we believe that assessment of the microbiota and diet should 
be combined with genetics as well as new modalities for investigation of gut motility 
in the search to uncover the pathogeneses of IBS.  Such studies may clarify whether 
IBS comprises aetiologically distinct entities beyond the main subtypes IBS-C and 
IBS-D, e.g. regarding the constitution of the intestinal microbiota, regarding small 
bowel motility and intestinal transit, and finally define the role of GC-C.  
6.2.5 Genetic	  testing	  and	  stratified	  medicine	  
Treatment of the monogenic disorder CF is now stratified according to genetic 
variants within the CFTR gene, providing carriers of the so-called gating mutations a 
specific treatment that restores CFTR function, improves life quality, lung function, 
nutrition and will probably give the patients a longer life.24 This is just one example 
of how genetics have helped to identify subtypes of known disorders and to develop 
specific treatments.  We have in the present work described a rare variant in the GC-
C pathway linked to the common disorders IBS and IBD, suggesting that genetic 
testing could help to identify relevant subtypes of these disorders that could be 
amenable for stratified treatment.   
Fortunately stratified treatment needs not be expensive. Colleagues at our own 
institution have done seminal work in monogenic diabetes showing that based on 
genetics some patients are better of with one tablet a day with an inexpensive drug, 
rather than the standard treatment, many injections per day of insulin.272  
6.2.6 Safeguarding	  the	  FGDS	  patients	  
FGDS patients may continue to provide precious insights in effects of GUCY2C but 
potential gains should be weighed against the inconvenience of repeated 
investigations. The FGDS cohort should now be followed prospectively, and all 
patients should be able to easily get in contact with physicians with expertise on their 
disorder.273 This could help to optimize patient management and identify factors 
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Først vil vi stille deg noen spørsmål om smerter eller ubehag i magen i løpet av 
det siste året. 
 
 
Med magesmerter eller ubehag, mener vi smerte eller ubehag i områdene merket A, 
B, C, D slik det er vist i diagram 1. (Vennligst ikke ta med krampe eller smerte i 
forbindelse med menstruasjonen og heller ikke smerter i brystet).  
 
A1. Har du i løpet av det siste året hatt smerter eller ubehag i magen? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 2. Har du i løpet av de tre siste månedene hatt ubehag eller smerte i magen? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
Dersom du svarer Sjelden eller aldri på spørsmål A1 og A2,  
vennligst gå til spørsmål B 1. 
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A 3. Hvordan er ubehaget eller smerten du har hatt de siste tre månedene 
sammenliknet med hva du har hatt det siste året? 
q Bedre de siste tre månedene 
q Verre de siste tre månedene 
q Omtrent det samme 
q Har ikke hatt ubehag eller smerte de siste tre månedene  
 
A 4. Når du i løpet av det siste året hadde ubehag eller smerte i magen, var de 
da kontinuerlig eller nesten kontinuerlig (uten opphold)? 
q Ja  
q Nei  
 




A 6.  Hvor er magen din lokalisert i forhold til diagrammet på forutgående side 




q D  
  
A 7. Hvis du har smerter flere typer smerter, hvor sitter den mest plagsomme 




q D  
 
A 8. I løpet av det siste året, har dine daglige aktiviteter blitt påvirket av ubehag 
eller smerte i magen? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
 




A 9. I løpet av det siste året, hvor alvorlig var ubehaget eller smerten i magen?  
q Veldig mild 
q Mild  
q Moderat 
q Sterk   
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A 10. I løpet av det siste året, ble ubehaget eller smerten i magen bedre eller 
forsvant den etter at du hadde hatt avføring? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 11. I løpet av et siste året, hadde du hyppigere avføring enn vanlig når 
ubehaget eller smerten begynte? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 12. I løpet av det siste året, hadde du sjeldnere avføring enn vanlig når 
ubehaget eller smerten begynte? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 13. I løpet av det siste året, hadde du løsere avføring enn vanlig når ubehaget 
eller smerten begynte? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 14. I løpet av det siste året, hadde du hardere avføring enn vanlig når 
ubehaget eller smerten begynte? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 15. I løpet av det siste året, ble ubehaget eller smerten bedre etter raping? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
Copywrite © 1999 Talley et al 
Oversettelse  Lind, Lunding og Berstad, UiB, 2003 - 4 - 
Noen ganger: mer enn en av ti uker 
Ofte: mer enn en av fire uker 
Svært ofte: mer enn halvparten av ukene 
A 16. I løpet av det siste året, forekom ubehaget eller smerten etter måltider?  
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 17. I løpet av det siste året, har ubehaget eller smerten vekket deg når du 
sov? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 18. I løpet av det siste året, har ubehaget eller smerten noen gang strålt mot 
ryggen  eller skuldrene? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 19. I løpet av det siste året, ble ubehaget eller smerten mindre når du bøyde 
deg fremover? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 20. I løpet av det siste året, når du hadde ubehaget eller smerten, varte det 
lenger enn 20 minutter? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
A 21. Dersom du har ubehag eller smerte i øvre del av magen (områdene 
merket A og B i diagram 1), blir det bedre når du har hatt avføring? 
q Ja  
q Ikke i det hele tatt eller sjelden  
q Jeg har ikke slik smerte. 
 
A 21. 1. Når du hadde ubehaget eller smerten i øvre del av magen, hadde du da 
oftere avføring? 
q Ja  
q Ikke i det hele tatt eller sjelden  
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A 21. 2. Når du hadde ubehaget eller smerten i øvre del av magen, hadde du da 
sjeldnere avføringer? 
q Ja  
q Ikke i det hele tatt eller sjelden  
 
A 21. 3. Når du hadde ubehaget eller smerten i øvre del av magen, hadde du da 
hardere avføringer? 
q Ja  
q Ikke i det hele tatt eller sjelden  
 
A 21. 4. Når du hadde ubehaget eller smerten i øvre del av magen, hadde du da 
løsere avføringer? 
q Ja  
q Ikke i det hele tatt eller sjelden  
 
A 22. I løpet av det  siste året når du hadde ubehaget eller smerten, var det 
vanligvis i et lite avgrenset område som du kunne peket på med en eller to 
fingre? 
q Ja  
q Nei  
 
A 23. I løpet av det siste året når du hadde ubehaget eller smerten, var det jevnt 
og kontinuerlig (det gikk ikke i bølger)? 
q Ja  
q Nei  
 
A 24. I løpet av det siste året, har du hatt episoder med kontinuerlig sterk 
smerte (i midten av øvre av magen eller i høyre øvre del av magen) som varte i 
30 minutter eller mer? 
q Ikke i det hele tatt   
q 1 eller 2 episoder med slik smerte  
q Mer enn 2 episoder med slik smerte 
 
A 25. Har du noen gang hatt en operasjon der galleblæren ble fjernet? 
q Ja  
q Nei  
 
 
Vennligst sjekk at du har svart på alle aktuelle spørsmål i del A. 
Vennligst begynn på del B. 
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Vi vil gjerne stille deg spørsmål om andre mageproblemer du måtte ha hatt det 
siste året . 
 
 
B 1. I løpet av det siste året, har du følt deg ubehagelig mett eller oppfylt like 
etter at du begynte å spise, slik at du ikke klarte å spise opp et normalt måltid? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
B 2. I løpet av det siste året, etter at du har spist normale måltider, har du hatt 
en ubehagelig følelse av at maten har stoppet opp i magen? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
B 3. I løpet av det siste året, har du vært kvalm (ville kaste opp men gjorde det 
ikke)? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
B 4. I løpet av det siste året, har du kastet opp uten at du selv eller medisiner 
du tok var årsaken til dette? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
B 5. I løpet av det siste året, har du kastet opp minst tre forskjellige dager hver 
uken i en tre måneds periode? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
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B 6. I løpet av det siste året, har du hatt brekninger (som om du kaster opp, 
uten at noe kommer opp)? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
B 7. I løpet av et siste året, har du hatt følelsen av å være ”stinn”, oppblåst eller 
at hele magen eser ut? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
B 8. I løpet av det siste året, har du sett at magen din har eset ut? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
B 9. I løpet av det siste året, hva har vært ditt mest plagsomme symptom i øvre 
del av  magen? (området A eller B i figur 1) (velg bare ett svar). 
q Magesmerter 
q Svie, ”brenning” i magen 
q Ubehag i magen (ikke smerte) 
q Oppblåsthet i hele magen 
q Kvalme 
q Maten ”stopper opp” i magen 
q ”Stinn”, full i magen 
q Ubehagelig mett like etter at du begynte å spise 
q Jeg har ikke noen symptomer fra øvre del av magen  
 
   
 
Vennligst sjekk at du har svart på alle spørsmålene i del B. 
Vennligst begynn på del C. 
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Del C 
Vi vil gjerne stille deg noen spørsmål om andre helseproblemer du måtte ha 
hatt i løpet av det siste året. 
 
 
C 1. I løpet av det siste året, har du vært plaget med gjentatt raping? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
C 2. I løpet av det siste året, har du har svelget mye luft?  
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
C 3. I løpet av det siste året, har du hatt følelse av klump i halsen når du ikke 
svelger? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
C 4. I løpet av det siste året, har du hatt vanskeligheter med å svelge fast eller 
flytende føde (mat eller drikke setter seg fast eller passerer unormalt nedover)? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
C 5. I løpet av det siste året, har du måttet gulpe opp mat, tygge den på nytt og 
enten spyttet det ut eller svelget den igjen? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
 
Hvis du har svart Sjelden eller aldri på spørsmål C 5, vær så snill å gå til 
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C 5.1. Sjedde dette ved anledninger hvor du hadde vært kvalm eller kastet opp? 
q Ja  
q Nei  
 
C 5. 2. Sluttet du med dette etter at du hadde gulpet opp mat som smakte syrlig 
eller surt? 
q Ja  
q Nei  
 
C 6. I løpet av det siste året, har du hatt brystbrann? Med dette mener vi 
brennende smerte eller ubehag bak brystbeinet stigende opp mot svelget. (Ikke 
ta med smerte på grunn av angina eller hjerteproblemer). 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
C 7. I løpet av et siste året, har du hatt smerte eller ubehag midt i brystet? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
 
Vennligst sjekk at du har svart på alle aktuelle spørsmål i del C. 
Vennligst begynn på del D. 
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Del D  
Vi vil gjerne stille deg noen spørsmål om tarmproblemer du måtte ha hatt i 
løpet av det siste året. 
 
 
D 1. I løpet av et siste året, har du hatt noen tarmproblemer? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D 2. I løpet av de siste tre månedene, har du hatt noen tarmproblemer? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D 3. I løpet av et siste året, har du hatt flere enn tre avføringer hver dag? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D 4. I løpet av et siste året, har du hatt færre enn tre avføringer hver uke? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D 5. I løpet av et siste året, har du hatt klumpete eller hard avføring? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D 6. I løpet av et siste året, har du hatt løse, grøtete eller vandig avføring? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
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D 7. I løpet av et siste året, har du følt at du fortsatt ikke var helt tømt etter at du 
har hatt avføring? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
  
D 8. I løpet av et siste året, har du måtte trykke hardt for å få avføring? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D9. I løpet av det  siste året, har du opplevd så øyeblikkelig trang til å ha 
avføring, at du måtte løpe til toalettet? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D10   I løpet av det  siste året, har du lagt merke til slim (hvitt slim) i avføring? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D11. I løpet av det  siste året, har du hatt en følelse av at endetarmsåpning din  
har vært blokkert mens du hadde avføring 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
D12. I løpet av det siste året, måttet presse fingeren inn i eller rundt 
endetarmsåpningen eller skjeden for å hjelpe avføringen ut? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
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D13. I løpet av det siste året, har du hatt vedvarende eller tilbakevendende 
verkende smerte eller trykk i endetarmsåpningen eller endetarmsområdet? 
q Sjelden eller aldri  
q Noen ganger 
q Ofte 
q Svært ofte 
q Nesten alltid  
 
 




D14. Da du hadde vedvarende eller tilbakevendende verkende smerte eller 
trykk i endetarmsåpningen eller endetarmsområdet, varte det da vanligvis  
q Fra sekunder til minutter og forsvant helt? 
q 20 minutter eller lenger? 
 
D15. Var det perioder av minst to ukers varighet mellom episodene med smerte 




D16. I løpet av det siste året, når du hadde treg eller løs avføring, har du lekket, 
hatt avføring eller blitt tilsølt uten ville det? 
q Aldri 
q En gang hver måned 
q To ganger hver måned 
q Mer enn to ganger hver måned 
 
D17. Skjedde dette (at du hadde avføring uten at du hadde kontroll over det) 
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Versjon 1.2.12                                                                  Kristin Kaasen Jørgensen 
THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS) 




 Les dette først: 
Undersøkelsen inneholder spørsmål om hvordan du har følt deg og hvordan du har hatt 
det DE SISTE TRE DAGENE. Sett kryss (X) ved det alternativet som passer best på 







Hvilke datoer dette gjelder: ______________________________________  
 
 
1. Har du i løpet av de siste tre dagene vært plaget av MAGESMERTER? 
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
2. Har du i løpet av den siste tre dagene vært plaget av SMERTER ELLER UBEHAG I 
 MAGEN SOM GIR SEG NÅR DU HAR HATT AVFØRING?  
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
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3. Har du i løpet av den siste tre dagene vært plaget av OPPBLÅSTHET? 
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
 
4. Har du i løpet av den siste tre dagene vært plaget av LUFTAVGANG?  
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
 
5. Har du i løpet av den siste tre dagene vært plaget av FORSTOPPELSE (problemer                        
med å tømme tarmen)?  
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
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6. Har du i løpet av den siste tre dagene vært plaget av DIARÉ (hyppig avføring)?  
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
 
7. Har du i løpet av den siste tre dagene vært plaget av LØS AVFØRING?  
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
 
8. Har du i løpet av de siste tre dagene vært plaget av HARD AVFØRING? 
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
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9. Har du i løpet av den siste tre dagene vært plaget av TVINGENDE 
AVFØRINGSBEHOV  (plutselig behov for å gå på toalettet for å tømme tarmen)?  
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
 
10. Har du i løpet av de siste tre dagene vært plaget av en FØLELSE AV         
UFULLSTENDIG TØMMING AV TARMEN ETTER AVFØRING? 
  
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
11. Har du i løpet av den siste tre dagene vært plaget av at du FØLER DEG METT LIKE 
 ETTER AT DU HAR BEGYNT PÅ ET MÅLTID? 
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
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12. Har du i løpet av den siste tre dagene vært plaget av at du FØLER DEG METT SELV 
LENGE ETTER AT DU ER FERDIG MED Å SPISE? 
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
 ¨ Meget alvorlige plager 
 
13. Har du i løpet av den siste tre dagene vært plaget av at MAGEN ER SYNLIG 
OPPBLÅST? 
 
 ¨ Ingen plager i det hele tatt 
 ¨ Ubetydelige plager 
 ¨ Milde plager 
 ¨ Moderate plager 
 ¨ Ganske alvorlige plager 
 ¨ Alvorlige plager 
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Helseproblemer siste 30 døgn 
 
På den neste siden nevnes noen vanlige helseplager. Vi vil be deg om å vurdere hvert enkelt 
problem/symptom, og oppgi i hvilken grad du har vært plaget av dette i løpet av de siste tretti 




Hvis du føler at du har vært en del plaget med forkjølelse/influensa siste måned og varigheten av 
plagene var ca. en uke, fylles dette ut på følgende måte: 
Sett ring rundt tallet som passer best. 
 
 













1. Forkjølelse, influensa 0 1 (2) 3 7 
 
NB! Det er viktig at du fyller ut både hvor plaget du har vært, og omtrent antall dager du har 
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Helseproblemer siste 30 døgn 
 
Nedenfor nevnes noen alminnelige 
helseproblemer  














1. Forkjølelse, influensa .....................  0 1 2 3 …………. 
2. Hoste, bronkitt ................................  0 1 2 3 …………. 
3. Astma .............................................  0 1 2 3 …………. 
4. Hodepine ........................................  0 1 2 3 …………. 
5. Nakkesmerter .................................  0 1 2 3 …………. 
6. Smerter øverst i ryggen .................  0 1 2 3 …………. 
7. Smerter i korsrygg ..........................  0 1 2 3 …………. 
8. Smerter i armer ..............................  0 1 2 3 …………. 
9. Smerter i skuldre ............................  0 1 2 3 …………. 
10. Migrene ..........................................  0 1 2 3 …………. 
11. Hjertebank, ekstraslag ...................  0 1 2 3 …………. 
12. Brystsmerter ...................................  0 1 2 3 …………. 
13. Pustevansker .................................  0 1 2 3 …………. 
14. Smerter i føttene ved anstrengelser 0 1 2 3 …………. 
15. Sure oppstøt, «halsbrann» .............  0 1 2 3 …………. 
16. Sug eller svie i magen ....................  0 1 2 3 …………. 
17. Magekatarr, magesår .....................  0 1 2 3 …………. 
18. Mageknip .......................................  0 1 2 3 …………. 
19. «Luftplager» ...................................  0 1 2 3 …………. 
20. Løs avføring, diaré .........................  0 1 2 3 …………. 
21. Forstoppelse ..................................  0 1 2 3 …………. 
22. Eksem ............................................  0 1 2 3 …………. 
23. Allergi .............................................  0 1 2 3 …………. 
24. Hetetokter ......................................  0 1 2 3 …………. 
25. Søvnproblemer ..............................  0 1 2 3 …………. 
26. Tretthet ...........................................  0 1 2 3 …………. 
27. Svimmelhet ....................................  0 1 2 3 …………. 
28. Angst ..............................................  0 1 2 3 …………. 
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BACKGROUND
Familial diarrhea disorders are, in most cases, severe and caused by recessive muta-
tions. We describe the cause of a novel dominant disease in 32 members of a Nor-
wegian family. The affected members have chronic diarrhea that is of early onset, 
is relatively mild, and is associated with increased susceptibility to inflammatory bow-
el disease, small-bowel obstruction, and esophagitis.
METHODS
We used linkage analysis, based on arrays with single-nucleotide polymorphisms, 
to identify a candidate region on chromosome 12 and then sequenced GUCY2C, en-
coding guanylate cyclase C (GC-C), an intestinal receptor for bacterial heat-stable 
enterotoxins. We performed exome sequencing of the entire candidate region from 
three affected family members, to exclude the possibility that mutations in genes 
other than GUCY2C could cause or contribute to susceptibility to the disease. We 
carried out functional studies of mutant GC-C using HEK293T cells.
RESULTS
We identified a heterozygous missense mutation (c.2519G→T) in GUCY2C in all af-
fected family members and observed no other rare variants in the exons of genes in 
the candidate region. Exposure of the mutant receptor to its ligands resulted in mark-
edly increased production of cyclic guanosine monophosphate (cGMP). This may 
cause hyperactivation of the cystic fibrosis transmembrane regulator (CFTR), leading to 
increased chloride and water secretion from the enterocytes, and may thus explain 
the chronic diarrhea in the affected family members.
CONCLUSIONS
Increased GC-C signaling disturbs normal bowel function and appears to have a 
proinflammatory effect, either through increased chloride secretion or additional 
effects of elevated cellular cGMP. Further investigation of the relevance of genetic 
variants affecting the GC-C–CFTR pathway to conditions such as Crohn’s disease 
is warranted. (Funded by Helse Vest [Western Norway Regional Health Authority] 
and the Department of Science and Technology, Government of India.)
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Chronic diarrhea is a health prob-lem that poses challenges with respect to both diagnosis and treatment. The irrita-
ble bowel syndrome affects 15 to 20% of adults 
and is a common cause of diarrhea.1 Other causes 
include inflammatory bowel disease, infections, 
paraneoplastic hormones, celiac disease, malab-
sorption syndromes, and bacterial overgrowth in 
the small intestine.2 In addition to organic causes, 
psychological factors have an important effect on 
bowel function.1
Recent studies have focused on the importance 
of genetic factors in the development of chronic 
diarrhea3-5 because genetic factors can provide in-
sight into the pathophysiology of intestinal dis-
eases and point to new treatments. The irritable 
bowel syndrome aggregates strongly in families,6 
and the genetic predisposition to Crohn’s disease, 
particularly ileitis,7 is well documented,3 but no 
major genes causing these disorders have been 
found. Both diseases are considered to be multi-
factorial, and the causes include genetic suscepti-
bility variants and environmental factors. Rare 
inherited forms of chronic diarrhea have been re-
ported4; nearly all of these are severe, autosomal 
recessive, single-gene diseases that are manifest-
ed in the newborn period.
There is a fine balance between intestinal ab-
sorption and secretion of water and electrolytes.2,8,9 
The secretory capacity of the small intestine is 
substantial, as evidenced by the potentially life-
threatening secretory diarrhea that results from 
enterotoxigenic Escherichia coli and Vibrio cholerae in-
fections.9 Heat-stable enterotoxins from E. coli bind 
to intestinal guanylate cyclase C (GC-C) receptors, 
resulting in elevated levels of cellular cyclic gua-
nosine monophosphate (cGMP). cGMP elicits a 
signaling cascade involving protein kinases and 
the cystic fibrosis transmembrane conductance 
regulator (CFTR) (Fig. 1), ultimately causing in-
creased chloride secretion through CFTR. This 
creates an osmotic drive that results in the secre-
tion of sodium ions, and hence water, into the in-
testinal lumen (Fig. 1).2,9,10
We evaluated a large family (Fig. 2A) with a 
dominantly inherited, fully penetrant syndrome of 
chronic diarrhea and dysmotility. Other conditions 
present in some members of this family included 
Crohn’s disease, small-bowel obstruction, and 
esophagitis with or without esophageal hernia. 
We performed whole-genome single-nucleotide-
polymorphism (SNP)–based linkage analysis, as 
well as exome sequencing, and identified a het-
erozygous activating mutation in GUCY2C, encod-
ing GC-C. We thus established a genetic cause 
for this novel inherited disease.
Me thods
Participants
We studied 32 affected persons from three branch-
es of the same family (Fig. 2A), as well as 14 unaf-
fected family members. We obtained written in-
formed consent from all the participants in the 
study. The affected family members were examined 
by a gastroenterologist and completed question-
naires (Rome II and ad hoc forms) regarding bowel 
symptoms. The study was approved by the region-
al ethics committee of Western Norway.
Detection of Mutations
Genomic DNA was purified from blood with the 
use of the QIAsymphony system (Qiagen). Whole-
genome genotyping of SNPs was performed with 
the use of GeneChip Human Mapping 250K NspI 
array (Affymetrix). All exons and flanking intron 
sequences of GUCY2C (National Center for Bio-
technology Information [NCBI] reference se-
quence NM_004963.3), were amplified and se-
quenced by means of standard methods. Exome 
sequencing was performed with the use of HiSeq 
(Illumina) (for details, see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org).
Site-Directed Mutagenesis
We generated mutant complementary DNA (cDNA) 
containing the c.2519G→T [p.Ser840Ile] as de-
scribed previously.11 Nonmutant and mutant GC-C 
cDNAs were cloned into the mammalian expres-
sion vector pcDNA3 (Invitrogen), and the respective 
proteins (nonmutant GC-C and mutant GC-CS840I) 
were transiently expressed in HEK293T cells.11
Characterization of Mutant Protein 
GC-CS840I
We measured ligand-stimulated GC-C activity in 
intact cells 72 hours after transfection, after the 
addition of varying concentrations of heat-stable 
enterotoxin (STa) or uroguanylin (for 15 minutes) 
or guanylin (for 60 minutes).11 For in vitro gua-
nylate cyclase assays, membranes were prepared 
from transfected cells.11 Details are provided in 
the Supplementary Appendix.
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Heterodimerization and Interaction of GC-C
To monitor heterodimerization, plasmids harbor-
ing either nonmutant GC-C fused at the C-ter-
minal to glutathione S-transferase11 or mutant 
GC-CS840I were mixed in varying ratios and co-
transfected. Seventy-two hours after transfection, 
solubilized membrane protein was incubated with 
glutathione beads for 1 hour and then washed, 
and protein bound to the beads was detected by 
Western blot analysis (for details, see the Supple-
mentary Appendix).
Statistical Analysis
Linkage analysis was used to determine the can-
didate region for the mutation in the family. Mul-
tipoint parametric linkage analysis and haplotyp-
ing were performed with the use of the Allegro 
program, version 2, on a set of 45,000 SNPs pruned 
for strong local linkage disequilibrium. Details 




We studied 32 affected family members (14 females 
and 18 males), with a mean age of 44 years (range, 
2 to 89), and examined their medical histories. 
Family branch A came to our attention first, when 







Increase in Ca2+ 
results in CaR 















Figure 1. Signaling Mechanisms Mediated by Guanylate Cyclase C (GC-C).
GC-C expressed on the surface of enterocytes serves as the receptor for the endogenous ligands uroguanylin and 
guanylin or for heat-stable enterotoxins produced by enterotoxigenic Escherichia coli. Guanylin-family hormones are 
synthesized in the intestine and released both luminally and into the circulation. Uroguanylin exerts a natriuretic ef-
fect in the kidney. Ligand binding to GC-C increases intracellular levels of cyclic guanosine monophosphate (cGMP). 
The cGMP activates cGMP-dependent protein kinase II (PKGII) and inhibits the activity of a cyclic AMP (cAMP) 
phosphodiesterase, PDE3, thereby cross-activating cAMP–dependent protein kinase (PKA). PKGII and PKA phos-
phorylate the cystic fibrosis transmembrane conductance regulator (CFTR), increasing its chloride-secreting activity. 
In addition, cGMP enhances duodenal bicarbonate secretion through an unknown channel in a CFTR-dependent 
manner. These processes are involved in the maintenance of fluid and ion homeostasis. The cGMP also directly 
activates cyclic nucleotide gated channels (CNGs), leading to Ca2+ influx. Elevated intracellular Ca2+ levels activate 
calcium-sensing receptors (CaRs), promoting cell differentiation and migration. GC-C signaling is terminated by 
hydrolysis of cGMP to GMP by a cGMP-dependent phosphodiesterase, PDE5.10 NHE3 denotes sodium–hydrogen 
exchanger 3.
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ted to the hospital owing to dehydration (Fig. 2A, 
and Table 1 in the Supplementary Appendix). The 
affected family members in branch A typically had 
a history of chronic diarrhea that started in in-
fancy and was fairly constant over the years but 
that tended to subside by middle age in some per-
sons. The results of colonoscopic examinations 
of affected family members in branch A were es-
sentially normal (Table 1 in the Supplementary Ap-
pendix). Across all branches, the affected family 
members had an average of 3.6 stools per day 
(range, 0.3 to 20.0); the stools typically had a wa-
tery or loose consistency and were accompanied 
by meteorism and in some cases abdominal pain. 
The pattern of inheritance was autosomal domi-
nant, with some variation in expression. Four of 
the 32 cases (in family members C-VI2, B-VI1, 
B-VI3, and C-VII3) had previously been diagnosed 
as the irritable bowel syndrome, although they did 
not strictly meet the Rome II criteria.12 However, 
5 other cases (in family members A-IV1, A-V3, 
A-VI6, B-VII4, and B-VII5) did meet these criteria.
Some members of family branches B and C 
had more severe phenotypes (Table 1 in the Sup-
plementary Appendix). Ten family members un-
derwent laparotomy for suspected bowel obstruc-
tion; in eight of them (including family member 
B-IV1, who is not included in Table 1 in the Supple-
mentary Appendix), obstruction resulting from 
volvulus, adhesional bands, or ileal inflammation 
was confirmed. Two family members with bowel 
obstruction had anatomical variants in the ileo-
cecal region, such as a partly nonfixated ascend-
ing colon and slits in the ileal mesenterium. Three 
family members with bowel obstruction (B-V2, 
B-V3, and C-VI3) underwent a second operation 
to resolve adhesions, and family members C-VI3 
and B-IV1 were described as having adhesional-
band obstruction, even on the basis of the first 
laparotomy. Five family members with bowel ob-
struction (B-V2, B-V3, B-VI5, B-VI7, and B-VI9) 
eventually underwent resection of the terminal il-
eum and in some cases also the cecum; four of the 
five had verified or suspected Crohn’s disease 
(Table 1 in the Supplementary Appendix). In ad-
dition, Crohn’s disease was diagnosed in family 
members B-VI8 and C-VI2, and this diagnosis was 
suspected in family member C-V1. Family mem-
ber A-VI6 received a diagnosis of possible eosino-
philic enteritis.
Eight family members had been hospitalized 
for dehydration, metabolic acidosis, and electro-
lyte disturbances when they were newborns (Ta-
ble 1 in the Supplementary Appendix). They were 
found to have hyponatremia, hypokalemia, and in 
some cases also hypomagnesemia and hypocal-
cemia, accompanied by abdominal distention and 
dilatation of the small intestine. None had a con-
firmed infectious disease. Hirschsprung’s disease 
was ruled out in three of these family members, 
including B-VII1, who at 2 years of age had pe-
riods of constipation alternating with diarrhea. 
Seven other family members were hospitalized for 
dehydration at various times later in life, usually 
with infectious gastroenteritis, which, according 
to some of the family members, was followed by 
a prolonged period of recovery (Table 2 in the 
Supplementary Appendix). Several other condi-
tions that members of this family had may be as-
sociated with this inherited condition (Table 2 in 
the Supplementary Appendix), including urolithi-
asis (in four family members), vitamin B12 defi-
ciency (in six) and esophagitis with or without 
esophageal hernia (in five). We observed no evi-
dence of behavioral disturbances13 or a tendency 
toward obesity or excessive leanness.14 Most of the 
family members reported food sensitivity, and sev-
eral limit their intake of fruits, vegetables, and 
sweets.
Potentially Causative Mutation
Linkage analysis of samples from 11 affected mem-
bers and 14 healthy members of family branch A 
revealed only one significant shared region in the 
affected members, on the short arm of chromo-
some 12 (12p), with a maximum LOD score of 5.1 
(Fig. 1 in the Supplementary Appendix). A haplo-
type spanning approximately 2.9 megabases (Mb) 
(base pairs 14,466,726 to 17,410,570 from the start 
of 12p) showed complete cosegregation with the 
disease in the family. The region contained 28 pu-
tative protein-coding genes (Fig. 2B). Among these, 
GUCY2C (Fig. 2B) was the best candidate, because 
it encodes GC-C, an intestinal transmembrane re-
ceptor with known function in heat-stable entero-
toxin–mediated diarrhea.10 Sequence analysis iden-
tified a heterozygous base substitution, c.2519G→T, 
in exon 22 (Fig. 2C), predicting the replacement 
of the amino acid serine in codon 840 with iso-
leucine (p.Ser840Ile). Whole-exome sequencing 
in 3 persons (1 from each family branch) did not 
identify any other rare coding variant (Table 3 
in the Supplementary Appendix). Using Sanger 
sequencing, we found the GUCY2C c.2519G→T mis-
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sense mutation to be present in all affected fam-
ily members. We did not find this mutation in 
the NCBI human dbSNP database (build 132) or 
in 190 local healthy blood donors. None of the 14 
unaffected family members we tested carried the 
mutation.
The amino acid Ser840 is highly conserved 
among mammalian GC-C proteins15 and also in 
chicken and zebrafish (Fig. 2 in the Supplemen-
tary Appendix). The substitution is located in the 
catalytic domain (Fig. 2D), and we hypothesized 
that it may alter the guanylate cyclase activity of 
the mutant receptor.
Functional Characterization of the Mutation
We performed biochemical experiments using in-
tact transfected cells (Fig. 3, and Fig. 3 in the 
Supplementary Appendix) and membranes iso-
lated from these transfected cells (Fig. 4 through 
9 in the Supplementary Appendix), expressing ei-
ther normal (nonmutant) or mutant (S840I) pro-
tein in equal amounts; the results of Western blot 
analy sis are shown in Figure 3A, and in Figures 3 
and 4 in the Supplementary Appendix. The basal 
GC-C enzyme activity and cellular cGMP levels 
(Fig. 3A, and Fig. 4 and 5 in the Supplementary 
Appendix) and affinities of ligands (heat-stable 
enterotoxin, uroguanylin, and guanylin) (Fig. 7 
and 8 in the Supplementary Appendix) were simi-
lar in cells expressing the normal receptor and 
those expressing the mutant receptor. However, 
heat-stable enterotoxin (Fig. 3A and 3B, and Fig. 
4 and 6 in the Supplementary Appendix), urogua-
nylin (Fig. 3C), and guanylin (Fig. 3 in the Sup-
plementary Appendix) activated the mutant re-
ceptor to a greater extent than the nonmutant 
receptor. When cells were treated with 10−7 M 
heat-stable enterotoxin (Fig. 3B), 10−6 M uroguany-
lin (Fig. 3C), or 10−6 M guanylin (Fig. 3 in the 
Supplementary Appendix), cGMP production was 
increased by a factor of 7 to 8 (in the case of heat-
stable enterotoxin), 5 (in the case of uroguanylin), 
or 3 to 4 (in the case of guanylin) with the mu-
tant receptor, as compared with the nonmutant 
receptor. With respect to heat-stable enterotoxin, 
there was no significant difference between mu-
tant and nonmutant receptors in the concentra-
tion required for half-maximal activation (EC50) of 
the receptor (Fig. 3B). In contrast, with respect to 
uroguanylin, the EC50 of the mutant receptor 
was lower than that of the nonmutant receptor 
by a factor of about 5 to 6 (Fig. 3C), indicating 
that uroguanylin acts more potently on the mu-
tant receptor. This suggests that the concentra-
tions of uroguanylin present in the intestine 
could result in abnormally elevated levels of cel-
lular cGMP in intestinal cells harboring the mu-
tant receptor.
In patients who are heterozygous for the muta-
tion, nonmutant and mutant receptors may be co-
Figure 2 (facing page). Identification of a Pathogenic Mutation in a Large Family with Chronic Diarrhea.
Panel A shows the pedigree of the family. All affected males (black squares) except B-IV1 and C-IV1 and all affected 
females (black circles) except A-IV5 and B-IV3 were investigated. The inheritance pattern is autosomal dominant, 
and linkage analysis was performed on samples from 14 healthy members and 11 affected members of branch A. 
The numbers of the generations are shown in Roman numerals to the left. Family members in each generation are 
designated by Arabic numbers from left to right, starting on 1 within each branch (with numbers shown only for the 
first and last person within each branch). Information about disease status in the affected members in generations 
I, II, and III was limited; therefore these persons are shown as unaffected (white squares or circles). Slashes denote 
deceased family members. Panel B shows the map of chromosome 12 and the 2.9-Mb region identified by linkage 
analysis (www.ensembl.org). The region on the short arm of chromosome 12 (p13.1 to p12.3) extends from base 
pair 14,466,726 to base pair 17,410,570 from the start of the short arm (according to NCBI Build 36.3). It contains 28 
putative protein-coding genes, including GUCY2C (red circle), which is known to be the receptor for the E. coli heat-
stable enterotoxin. Panel C shows the heterozygous missense mutation (c.2519G→T, arrow) in exon 22 in GUCY2C, 
which was found in all affected family members. This base change predicts the replacement of the amino acid ser-
ine in codon 840 with isoleucine [p.Ser840Ile] in the GC-C protein. Panel D shows the domain organization of GC-C. 
The GC-C protein contains an extracellular domain that binds its ligands. A single transmembrane domain is followed 
by a juxtamembrane domain and a kinase homology domain that bears sequence similarity to protein kinases. This 
is followed by a linker region and finally the C-terminal guanylate cyclase domain. Ligand binding to the extracellular 
domain results in activation of the catalytic domain, leading to increased cGMP production. GC-C forms oligomers 
in cells. A homodimer is shown; the catalytic domains of guanylate cyclases are functional only when in the context 
of a dimer. Highlighted in the red box is the position of S840 (red sphere). Numbers indicate amino acid positions 
of human GC-C, which includes a signal sequence predicted to be 23 amino acids long. The modeling of the various 
domains was performed as described previously.10
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expressed in a single cell. We therefore engineered 
the coexpression of a nonmutant receptor (fused 
with glutathione S-transferase) and the mutant 
receptor in HEK293T cells. The mutant receptor 
along with the glutathione S-transferase–tagged 
nonmutant receptor was captured by glutathione 
beads (Fig. 9 in the Supplementary Appendix), 
indicating the formation of heterodimers. There 
was a significant increase in the production of 
cGMP when the two receptors were coexpressed 
(in a 1:1 ratio), as compared with the production 
of cGMP when the nonmutant receptor was ex-
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pressed alone (2:0 or 1:0 ratio) (Fig. 3D). This el-
evated activity was not as high as the activity ob-
served with the mutant receptor alone (0:1 or 0:2 
ratio), indicating that heterodimerization of the 
nonmutant and mutant receptors may blunt the 
ligand-mediated hyperactivation of the mutant 
receptor.
Discussion
We describe a previously unrecognized disease 
characterized by familial diarrhea and define its 
genetic cause. The chronic diarrhea showed an 
inheritance pattern that was consistent with a 
dominant mutation in an autosomal gene, and 
we observed a heterozygous missense mutation, 
c.2519G→T [p.Ser840Ile], in GUCY2C in all affect-
ed family members (Fig. 2C and 2D). Subsequent 
functional analyses of the mutation in cell culture 
suggested that it effects a gain of function, in that 
it increases ligand-mediated activation of GC-C 
with subsequent intracellular accumulation of 
cGMP (Fig. 3). Persons with this mutation would 
therefore be prone to the production of compara-
tively high levels of cGMP in response to normal 
levels of endogenous ligands.
The importance of GC-C signaling and CFTR 
function in infectious bowel disease is well es-
tablished.8-10,16 The binding of heat-stable entero-
toxin to GC-C greatly increases the formation of 
intracellular cGMP, which activates protein kinase 
GII, leading to phosphorylation of the CFTR chan-
nel.10 This results in efflux of Cl− (or HCO3− in 
the duodenum) and water into the intestinal lu-
men (Fig. 1), as well as reduced sodium absorp-
tion through inhibition of the sodium–hydrogen 
exchanger 3 (NHE3).16 The disease we describe 
here may thus represent a “knock-in” genetic 
model of enterotoxigenic E. coli infection, with 
increased signaling through cGMP explaining 
the diarrhea in the affected family members, 
who were particularly prone to diarrhea, dehydra-
tion, and electrolyte disturbances soon after 
birth (Table 1 in the Supplementary Appendix). 
This is consistent with the observation that 
GC-C in the intestine is most highly expressed in 
newborns and declines during the first months 
of life to the level found in adults.17
The symptoms in the family members we ex-
amined overlapped with those of common disor-
ders such as the irritable bowel syndrome (par-
ticularly in nine family members) and Crohn’s 
disease (which was confirmed or suspected in 
seven members). This familial diarrhea syndrome 
also appears to confer a predisposition in the af-
fected family members to small-bowel obstruc-
Figure 3 (facing page). Functional Analyses of Mutant GC-C Protein in HEK293T Cells.
Panel A shows heat-stable enterotoxin (ST)–mediated cyclic GMP (cGMP) production by GC-C. HEK293T cells were 
transfected with plasmids that allowed expression of either nonmutant GC-C or mutant GC-C (S840I). Equivalent 
expression of nonmutant or mutant GC-C was observed on Western blot analysis with the use of a monoclonal anti-
body to GC-C (inset). GC-C migrates as two differentially glycosylated proteins of molecular weight 130 and 145 kD.11 
Cells were treated with medium alone or with ST (10−7 M) for 15 minutes, and intracellular cGMP levels were mea-
sured by radioimmunoassay. Data shown are from one experiment (two measurements), and the experiment was 
 repeated twice. T bars indicate standard errors. Panel B shows the dose response with ST. Cells expressing either 
nonmutant GC-C or mutant GC-C (S840I) were treated for 15 minutes with varying concentrations of ST as indicat-
ed, and intracellular cGMP levels were measured. The values in the graph are the mean values of a representative 
experiment; I bars indicate standard errors. The experiment (two measurements) was repeated three times with 
similar findings, and the concentration required for half-maximal activation (EC50 nanomolar values) was calculated 
from six measurements. EC50 values did not differ significantly between nonmutant and mutant GC-C. Panel C 
shows the dose response with uroguanylin. Cells expressing either nonmutant GC-C or mutant GC-C (S840I) were 
treated for 15 minutes with varying concentrations of uroguanylin as indicated, and intracellular cGMP levels were 
measured. The values in the graph are the mean values in a representative experiment; I bars indicate standard er-
rors. The experiment (two measurements) was repeated three times with similar findings, and the EC50 values were 
calculated from six measurements. EC50 (micromolar values) differed significantly between nonmutant and mutant 
GC-C (P<0.001). Panel D shows heterodimerization of nonmutant GC-C and mutant GC-C (S8401). Indicated ratios 
of plasmids expressing either nonmutant GC-C tagged with glutathione S-transferase (GST) or mutant GC-C were 
cotransfected in HEK293T cells. Nonmutant GC-C–GST migrates at a size of approximately 160 kD owing to the  
C-terminal fusion of GST, and mutant GC-C migrates at 130 and 145 kD. The relative expression of the two proteins 
was monitored by Western blot analysis with the use of a monoclonal antibody to GC-C. At 72 hours after transfec-
tion, cells were treated with ST (10−7 M) for 15 minutes, and intracellular cGMP was measured by radioimmunoas-
say. Data shown represent the means of duplicate measurements, and the experiments were repeated twice. T bars 
indicate standard errors.
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tion (which has occurred in eight family members) 
and esophagitis or esophageal hernia (in five 
members). Thus, the spectrum of symptoms seen 
in our patients suggests that the increased level of 
cGMP present in cells harboring the c.2519G→T 
[p.Ser840Ile] mutation affects inflammation and 
motility in the gut.
cGMP signaling has been linked to the regu-
lation of inflammation and cell proliferation.18,19 
It has been shown that mice deficient in Gucy2c 
have a reduced inflammatory response to a colitis-
inducing agent, owing to reduced expression of 
proinflammatory molecules.20 The possibility that 
increased cGMP signaling enhances the expression 
of proinflammatory cytokines should be tested, 
since that may explain the susceptibility to ileitis 
in our patients. An increased risk of inflamma-
tory bowel disease is also seen in connection with 
other conditions that cause intestinal electrolyte 
disturbances. This increased risk is observed in 
mice that are deficient in Nhe321 and in patients 
with congenital chloride diarrhea.22 Changes in 
electrolyte homeostasis and increased permeabil-
ity23,24 may cause a disturbance in intestinal bar-
rier function, which was recently proposed as a 
primary contributor to the development of inflam-
matory bowel disease.25,26 Disturbed intestinal 
barrier function may also be caused by chronic 
changes in tight-junction function or assembly (or 
both),26 which are affected by GC-C signaling.27
The terminal ileum in the affected family mem-
bers we examined appeared to be susceptible to 
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small-bowel obstruction. Eight of 33 family mem-
bers underwent laparotomy owing to small-bowel 
obstruction (Table 1 in the Supplementary Ap-
pendix); some family members required a second 
or even third laparotomy owing to reobstruction, 
which is frequently related to the formation of 
adhesions. All the affected family members had 
meteorism, and dilatation of the small intestine 
was seen during quiescent phases in many of them 
(Table 1 in the Supplementary Appendix). The lat-
ter, which is also observed in children with con-
genital chloride diarrhea,22 may result from in-
creased fluid in the intestine, reduced tone of 
smooth muscle, or both. The ileocecal junction 
was not dilated on radiographs or at surgery, and 
it may represent a bottleneck for the increased 
fluid formation. Mechanical strain or abnormal 
mobility in the ileocecal region could increase 
the risk of recurrent colic and bowel obstruc-
tion.28 The molecular mechanisms underlying the 
disturbed motility in the gut and the meteorism 
in these patients are not known.
Both guanylin and cGMP have a relaxing ef-
fect on smooth-muscle cells in the gastrointesti-
nal tract.29,30 Levels of cGMP are altered by several 
effectors in the intestine, including other natri-
uretic peptides and the strong muscle relaxant 
and secretory agent, vasoactive intestinal peptide,31 
suggesting the possibility of cross-talk between 
these signaling molecules and GC-C.32,33 Such 
cross-talk is of interest in a wider perspective, be-
cause (pro)uroguanylin is also secreted into the 
bloodstream and affects renal electrolyte trans-
port in humans,34 as well as behavior13 and sa-
tiety (as part of the gut–brain axis)14 in animals. 
GUCY2C is expressed in the brain,13,14 but we ob-
served no symptoms consistent with an effect of 
the mutant protein on the central nervous system.
Our data are consistent with those obtained 
through study of the role of GC-C in intestinal 
hydration, meteorism, and bowel function.18,20,35 
Both low activity35 and high activity of this re-
ceptor-cyclase may interfere with homeostasis in 
the intestine. To our knowledge, no common 
low-risk susceptibility variants in GUCY2C for ei-
ther the irritable bowel syndrome or inflamma-
tory bowel disease have been reported.3,5 Forth-
coming genomewide association studies that 
use next-generation sequencing may reveal rare 
susceptibility variants. Also, variants in any of 
the genes related to the GC-C–CFTR pathway 
probably contribute to overall signaling through 
GC-C, making the whole pathway an interesting 
target for the investigation of diarrhea or consti-
pation of unknown cause.
In conclusion, we have identified an activating 
mutation in GUCY2C as the cause of a novel famil-
ial diarrhea syndrome, characterized by meteor-
ism, abdominal pain, dysmotility, and inflamma-
tory bowel disease. This finding highlights GUCY2C 
as a susceptibility gene for Crohn’s disease, small-
bowel obstruction, and functional gastrointesti-
nal diseases such as the irritable bowel syndrome 
and points to the GC-C–CFTR pathway as a tar-
get for a further search of mechanisms underly-
ing these conditions.
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Supplementary Material and Methods 
 
Authors’ contributions 
Clinical and molecular genetic aspects of this study were designed by TF, PMK, JA and NH.  
Studies on the molecular analysis of the mutant receptor were designed by SSV, NA and KH. 
Data were gathered by NA, BIH, RRT, KDP, SLT, SEL, DB, HB, JA and TF. Data were 
analyzed by NA, BIH, RRT, SJ, BH, HB, JA, NH, SSV, PMK and TF. PMK, SSV, NH and 
SEL vouch for the data and the analyses. TF was responsible for writing the paper, including 
the first draft, in close collaboration with SSV and with contributions mainly from NA, PMK, 
RRT, SJ, BH, BIH, HB and NH. The decision to publish the paper was a joint one amongst all  
authors. The generated data belong to the authors. There are no other agreements concerning 
confidentiality of the data. 
 
DNA analyses and mutation detection 
Whole genome SNP genotyping data are deposited in the Gene expression omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/), with accession number GSE31260. PCR primers for 
amplification of exons and flanking intronic sequences of GUCY2C were designed using the 
Oligo 6.3 program (National Bioscience, Plymouth, USA). Reference sequence for GUCY2C 
was NM_004963.3. PCR amplification was performed using standard procedures. DNA 
sequencing was performed using the ABI BigDye kit v1.1 and the ABI 3730 sequencer. Data 
analysis was assisted by use of the Seqscape software (ABI, Foster City, USA). 
 
Exome sequencing 
Samples were prepared for whole exome capture using Roche-Nimblegen's SeqCap EZ 
Exome v3 (64Mb capture region) and sequenced using the Illumina HiSeq to a median 
 3 
coverage of 74x according to manufacturer's protocol. 1  Following sequencing using a paired-
end 100 nt read length, sequences were analyzed with CASAVA v1.8 (Illumina Inc) followed 
by alignment with Burrows-Wheeler transformation. 2 PCR duplicates were removed with 
PICARD (http://picard.sourceforge.net) followed by base quality recalibration using Genome 
analysis tool kit. 3 SNPs and indels were called by SAMtools. 4 Variants with less than 8X 
sequencing depth and quality score ≤ 30 were excluded from analysis. Annovar 5 was used for 
variant annotation. Variant analysis was restricted to the chromosome 12 linkage interval at 
14,466,726-17,410,570. Median coverage of the CCDS-bases in the linkage interval was 95X, 
with 99% of bases covered at ≥10X. 
 
Linkage analysis 
Multi-point parametric linkage analysis and haplotyping was performed using the program 
Allegro v26 on a set of 45000 SNPs pruned for strong local LD. Files were handled by the Uni 
Computing Linux cluster FIMM at the Bergen Center for Computational Science. We used a 
fully penetrant dominant inheritance mode with population disease allele frequency of 0.001. 
Marker allele frequencies were estimated using data from all individuals in the analysis. 
Physical marker positions are given according to NCBI Build 36.3 
(http://www.ncbi.nlm.nih.gov/mapview/). 
 
Characterization of mutant protein GC-CS840I 
Ligand-stimulated GC-C activity was measured in cells 72 h post-transfection, following 
addition of varying concentrations of uroguanylin or heat-stable enterotoxin (ST) (for 15 
min), or guanylin (for 60 min).  ST was purified in the laboratory by procedures described 
earlier .7 Cells were then lysed in 0.1N HCl and cGMP measured by radioimmunoassay as 
described earlier 8, or by ELISA (Enzo Life Sciences). Cells were also directly lysed in SDS 
 4 
sample buffer and subjected to Western blot analysis using a monoclonal antibody to GC-C. 9 
For in vitro guanylate cyclase assays, membranes were prepared from transfected cells. 9 
Protein concentration was estimated by using a modification of the Bradford protein assay. 10 
 
Heterodimerization and interaction of wild-type (WT) and mutant GC-C  
To monitor heterodimerization, plasmids harboring WT GC-C fused at the C-terminus to 
GST (GC-C-GST)8 and mutant GC-CS840I were mixed in varying ratios for a total of 400 ng 
of DNA/well and co-transfected. In instances where only WT or mutant DNA (1:0 or 0:1) 
were to be transfected, vector control DNA was co-transfected to maintain the ratio of total 
DNA to lipid. 72 h post transfection, membrane protein (400 µg) was solubilized in 
interaction buffer (10 mM Tris-HCl pH 7.5, 5 µg/ml each of aprotinin, leupeptin and soybean 
trypsin inhibitor, 1% NP-40 and 5 mM β-mercaptoethanol), and solubilized protein incubated 
with 10 µL GSH beads for 1 h at 4 °C.  Following washing of the beads, protein bound to the 




Supplementary Figure 1  
 
LODscore on chromosome 12  
Whole genome linkage analysis using SNP-arrays identified only one significant region (4.13 
centimorgan; 14,466,726-17,410,570 basepairs from end of 12p) on chromosome 12 with a 
max LODscore of 5.1. This means that the odds for linkage versus no linkage for this region 
with the disease is 125892/1. Physical position in Mb (chromosome 12) is given in the figure 









Supplementary Figure 2 
 
Multiple protein sequence alignment of GC-C 
 
                    
Homo sapiens   794   DRLNFMLLPRLVVKSLKEKGFVEPELYEEVTIYFSDIVGFTTICKYSTPM   843 
 
Pan troglodytes   794   DRLNFMLLPRLVVKSLKEKGFVEPELYEEVTIYFSDIVGFTTICKYSTPM   843 
 
Canis lupus  792   DRLNFMLLPRLVVKSLKEKGIVEPELYEEVTIYFSDIVGFTTICKYSTPM   841 
 
Bos taurus         793   DQLNFMLLPRLVVKSLKEKGFVEPELYEEVTVYFSDIVGFTTICKYSTPM   842 
 
Mus musculus       769   DHLNFMLLPRLVVKSLKEKGIVEPELYEEVTIYFSDIVGFTTICKYSTPM   818 
 
Rattus norvegicus 793   DHLNFMLLPRLVVKSLKEKGIVEPELYEEVTIYFSDIVGFTTICKYSTPM   842 
 
Gallus gallus     791   DRLNFMLLPRPVVKSLKETGLVEPEFFEEVTIYFSDIVGFTTLCKYSTPM   840 
 
Danio rerio       574   DCLNFMLLPGPVVRSLKETGKVEPELFDEVTIYFSDIVGFTTLCHFSTPM   623 
 
 
The region of the GC-C protein surrounding the amino acid serine (S, red colour) in position 
840 in the protein is displayed, with sequences from different species aligned. The high 
degree of conserved amino acids in the whole region may indicate that this region is important 
for protein function.  Note residue tyrosine (Y, green colour) at position 820, which has been 
shown to be a site for inhibitory phosphorylation by c-src. 11 The Ser840 (conserved in all 













Supplementary Figure 3 













Guanylin-mediated cGMP production by GC-C. HEK293T cells were transfected with 
plasmids that allowed expression of either WT GC-C or mutant GC-CS840I. Equivalent 
expression of WT or mutant GC-C was observed on Western blot analysis using a monoclonal 
antibody to GC-C (left panel). Cells were either treated with medium alone, 1 µM or 10 µM 
guanylin. The experiment (n=2) was performed twice and data shown are the mean ± SEM of 
four determinations (*p < 0.0001).  
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Supplementary Figure 4 
 







Membrane fractions from cells transfected with plasmids encoding either WT GC-C or mutant 
GC-CS840I were prepared.  Expression of GC-C was monitored by Western blot analysis (left 
panel).  Guanylate cyclase assays were performed with membrane protein (50 µg) in the 
presence of 10 mM MgCl2, 1 mM GTP, 500 µM isobutyl methyl xanthine, with or without the 
addition of ST (10-7 M). Assays were incubated for 10 min at 37 °C, reactions stopped and 
cGMP produced measured by radioimmunoassay as detailed earlier. 8 Data shown are the 
mean ± SEM of duplicate determinations from a representative experiment, with experiments 
repeated thrice.  
 
    WT            S840I         
ST        -       +         -       + 
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Supplementary Figure 5 
 





Membrane fractions from cells transfected with plasmids encoding either WT GC-C or mutant 
GC-CS840I were prepared.  Membrane protein (50 µg) was used for guanylate cyclase assays 
performed in the presence of 10 mM MgCl2, 1 mM GTP, 500 µM isobutyl methyl xanthine 
without the addition of ST, which would represent basal guanylate cyclase activity. Assays 
were incubated for 10 min at 37 °C, reactions stopped and cGMP produced measured by 
radioimmunoassay as detailed earlier.8 Activity seen in untransfected cells was less than 10 % 
of that seen following transfection of GC-C (data not shown). Data shown in the graph are the 
mean ± SEM of duplicate determinations from a representative experiment. However, 
experiments were repeated twice and the table shows the mean ± SEM from kinetic analyses 







 Vmax (mM) K’ (mM) Hill 
WT 19.3 + 0.7 4.6 + 0.1 1.8 + 0.1 
S840I 21.1 +  0.9 5.2+ 0.7 1.7+ 0.1 
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Supplementary Figure 6 
 
 





Assays were performed with membrane protein (50 µg) prepared from transfected cells, in the 
presence of 10 mM MgCl2, 1mM GTP, 500 µM isobutyl methyl xanthine and ST (10-7 M). 
Incubations were for 10 min at 37 °C and cGMP produced was measured by 
radioimmunoassay as described earlier. 8 Data shown in the graph are the mean ± SEM of 
duplicate determinations from a representative experiment. Note different scales on the y-
axes. Experiments were repeated twice and the table shows the mean ± SEM from kinetic 
analyses of these data.  
 Vmax (mM) K’ (mM) Hill 
WT 50.7 + 3.2 2.7 + 0.7 1.8 + 0.1 
S840I 462.7 + 19 1.5 + 0.3 1.5 + 0.1 
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Supplementary Figure 7  
 






Membrane protein (50-100 µg) prepared from transfected cells was incubated with varying 
concentrations of  125I-labeled ST peptide8 for 1 h at 37oC.  Bound ST peptide was measured 
following filtration through GF/C filters (left panel).  Data analysis was performed using 
GraphPad Prism 5.  Representation of the data in a Scatchard Plot (right panel)  allows the 
determination of the dissociation constant (Kd) of ST binding to GC-C, from the slopes of the 
lines.  Data shown in the graph is from a representative experiment, as is the Bmax value in the 
table. The experiment was repeated thrice to obtain the Kd with values shown representing the 










 WT  S840I  
Bmax (pM)  9.1  9.4  
Kd (pM)  98.6 ± 10  103.7 ± 8  
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Supplementary Figure 8  
 













Membrane protein (50-100 µg) was incubated with ~ 100,000 cpm of 125I-labeled ST peptide 
(~ 2000 Ci/mmol) in the presence of the indicated concentration of uroguanylin (A) or 
guanylin (B).  Incubation was continued for 1 h at 37 °C following which samples were 
filtered through a GF/C filter and radioactivity associated with the membrane measured.  Data 
was analyzed by GraphPad Prism 5, and the Ki (concentration of ligand required to reduce the 
binding of radiolabelled ligand (ST) by 50 %) was estimated from non-linear regression 
 
 WT  S840I  
Ki (nM)  1.9 +  0.4  2.0 + 0.5  
 
 
 WT  S840I  
Ki (nM)  7.3 +  1.6  9.9 + 1.6  
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analysis.  The inverse of Ki is indicative of the affinity of the ligands for the receptor. Data 
shown is the mean ± SEM of experiments repeated three times, and the data indicate that there 
is no significant difference in the affinities of either uroguanylin or guanylin for the WT and 
mutant receptor  
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HEK293T cells were transfected with plasmids that express WT GC-C tagged with GST (GC-
C-GST) or mutant GC-CS840I, either singly, or in a 1:1 ratio. 72 h following transfection, 
membranes were prepared from transfected cells and solubilised as described earlier.8  Lysates 
were interacted with glutathione beads, and then subjected to Western blot analysis using a 
GC-C monoclonal antibody. Lanes 1-3 are samples prior to interaction with the beads. Lanes 
5,7,8 indicate the various complexes pulled down by GSH beads. The red box outlines the 
band corresponding to GC-CS840I that is pulled down along with GC-C-GST, indicating 
heterodimerization of the wild type and mutant receptors.  Note that no GC-CS840I interacts 
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Supplementary Table 2. Additional clinical characteristics of the affected family 
members. 
Four patients have had urolithiasis, six have vitamin B12-deficiency, five have esophagitis  ± 
esophageal hernia, six patients have hypertension, including two patients who developed this at young 









B12 deficiency Esophagitis±  
Esophageal hernia 
Hypertension 
A-IV1 F 89    Yes + hernia, 
Barret’s esophagus 
Yes 
A-IV4 F 82   Yes Yes + hernia Yes 
A-V1 F 59 GI-infections    Yes, aged 42 
A-V3 M 63 Fruit and 
vegetables 
    
A-V5 F 59 Fruit     
A-V6 M 49 Fruit Yes   Yes, aged 22 
A-V8 M 60 Fruit, grapes     
A-V10 M 67 Red meat     
A-VI2 F 28 Pregnancy   
GI-infections 
  Yes  
A-VI6 M 28  Yes x 2    
A-VI7 M 45      
B-V2 F 62 Fat, sweets 
GI-infections 
 Yes   
B-V3 F 65 Sweets,    
dairy products  
    
B-V5 F 69     Yes 
B-V7 M 73      
B-VI1 F 31 Sweets 
Carbonated 
soft-drinks   
GI-infections 
    
B-VI3 F 40 Sweets        
GI-infections 
    
B-VI5 M 45 Unknown     
B-VI7 M 43 Sensitive to 
certain types 
of food  
    
B-VI8 M 38 GI-infections     
B-VI9 M 41 Dark bread, 
sweets 
Yes Yes   
B-VI10 M 44 Certain types 
of food 
    
B-VII1 M 2      
B-VII2 M 3 GI-infections     
B-VII3 M 17 GI-infections 
Fruit juices 
    
B-VII4 M 16 Cow’s milk 
Fruits           
GI-infections 
    
B-VII5 M 12 Milk         
Fruits           
GI-infections 
    
C-V1 F 65 GI-infections  Yes Yes Yes 
C-VI2  F 44 GI-infections Yes Yes   
C-VI3 F 41 GI-infections  Yes Yes + hernia  
C-VII2 F 4 GI-infections     
C-VII3 M 17      
	  
Supplementary Table 3. Exome sequencing of the candidate region on chromosome 12. 
DNA from individuals A-V1, B-VI3 and C-VI3 representing the three branches of the family, was whole  
exome sequenced to a median exome coverage of 74X and coverage of 95X in the candidate region on  
chromosome 12. All variants in the coding parts (exons) of the candidate region (14,466,726-17,410,570 bp 
from start of chromosome 12) in any of the three patients  are listed. Positions are given in bp from start of  
short arm of chromosome 12. Only one common novel coding variant not present in the 1000 genomes or  
dbSNP was found; c.2519G>T in GUCY2C . In the candidate region, more than 99% of bases in the coding  
CDS were covered at ≥20X. 
	  Position Type of mutation Gene cDNA-change Protein-change dbSNP A-V1 B-VI3 C-VI3 
14469159	   missense ATF7IP c.1043A>T p.N348I rs2231909 T/T T/T A/T 
14478568	   missense ATF7IP c.1589A>G p.K530R rs3213764     A/G 
14548035	   missense PLBD1 c.1600C>G p.P534A rs1600 G/G G/G C/G 
14555862	   synonymous PLBD1 c.895T>C  rs10846013 T/C     
14579911	   missense PLBD1 c.793G>A p.V265I rs7957558 A/A A/A A/A 
14666289	   missense GUCY2C c.2519G>T p.S840I NOVEL G/T G/T G/T 
14685329	   synonymous GUCY2C c.2022C>T  rs10772800 T/T T/T T/T 
14721160	   missense GUCY2C c.843T>G p.F281L rs1420635 G/G G/G G/G 
14727344	   synonymous GUCY2C c.510C>T  rs56003832 C/T C/T C/T 
14867820	   synonymous C12orf60 c.684G>C  rs17761825   G/C   
14884706	   missense ART4 c.793G>A p.D265N rs11276 G/A A/A G/A 
14884875	   synonymous ART4 c.624C>T  rs3088189 C/T T/T C/T 
14885121	   synonymous ART4 c.378T>C  rs1861698 T/C C/C T/C 
14926348	   missense MGP c.304A>G p.T102A rs4236 A/G G/G A/G 
14986825	   synonymous ARHGDIB c.504G>C  rs4703 G/C     
14994872	   synonymous ARHGDIB c.42T>C  rs2430711 C/C C/C C/C 
15153446	   synonymous RERG c.408C>T  rs1055151 T/T T/T C/T 
15561004	   synonymous PTPRO c.1626T>C  rs1050646 T/C T/C   
15570387	   synonymous PTPRO c.2088C>A  rs6488782 C/A     
15624936	   synonymous PTPRO c.519G>A  rs3748299     G/A 
16238575	   synonymous SLC15A5 c.1563C>T  rs3942536 C/T   C/T 
16261095	   missense SLC15A5 c.1482T>A p.D494E rs1671511 A/A A/A A/A 
16288944	   missense SLC15A5 c.812C>T p.P271L rs1527014 T/T T/T T/T 
16289001	   missense SLC15A5 c.755G>T p.R252L rs1852450 G/T  G/T 
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